Karl Insogna, MD, FACP
Research & Publications
Biography
News
Research Summary
Dr. Insogna maintains active programs in both clinical and bench research.
In the clinical arena, Dr. Insogna is interested in the role of dietary protein in skeletal metabolism. Over the past decade, he and Dr. Jane Kerstetter from the University of Connecticut have established a new paradigm for the effect of dietary protein on calcium homeostasis. They have found that, contrary to the widely held view, increases in dietary protein within the physiologic range do not result in negative bone balance. Using dual stable calcium isotopes, they determined that the long-recognized hypercalciuria, which attends an increase in dietary protein, is quantitatively explained by improved intestinal calcium absorption, rather than increased bone resorption. In fact, the rate of resorption tends to slow as dietary protein is increased from low to high-normal. These data have led Drs. Insogna, Kerstetter, and Anne Kenney (from the University of Connecticut) to launch an NIH-funded, multi-center trial examining the impact of a dietary protein supplement on bone metabolism in postmenopausal women. Ongoing studies also seek to better define the cellular and molecular mechanisms by which dietary protein augments intestinal calcium absorption. Some of this work suggests a potential role for the calcium-sensing receptor, but alternative theories are currently being explored in the laboratory.
Dr. Insogna's most recent NIH grant is for a study to explore the role of sphingosine kinase in bone anabolism.
Specialized Terms: Role of dietary protein in skeletal metabolism; Factors that lead to skeletal disease in adult patients with X-linked hypophosphatemic rickets; Cellular mechanisms of PTH-induced bone resorption and bone anabolism; Effects of CSF1 in mature osteoclasts.
Extensive Research Description
Dr. Insogna maintains active programs in both clinical and bench research.
In the clinical arena, Dr. Insogna is interested in the role of dietary protein in skeletal metabolism. Over the past decade, he and Dr. Jane Kerstetter from the University of Connecticut have established a new paradigm for the effect of dietary protein on calcium homeostasis. They have found that, contrary to the widely held view, increases in dietary protein within the physiologic range do not result in negative bone balance. Using dual stable calcium isotopes, they determined that the long-recognized hypercalciuria, which attends an increase in dietary protein, is quantitatively explained by improved intestinal calcium absorption, rather than increased bone resorption. In fact, the rate of resorption tends to slow as dietary protein is increased from low to high-normal. These data have led Drs. Insogna, Kerstetter, and Anne Kenney (from the University of Connecticut) to launch an NIH-funded, multi-center trial examining the impact of a dietary protein supplement on bone metabolism in postmenopausal women. Ongoing studies also seek to better define the cellular and molecular mechanisms by which dietary protein augments intestinal calcium absorption. Some of this work suggests a potential role for the calcium-sensing receptor, but alternative theories are currently being explored in the laboratory.
Another area of active clinical investigation involves understanding the factors that lead to skeletal disease in adult patients with X-linked hypophosphatemic rickets. Research over the last decade has improved our understanding of the pathogenesis of hypophosphatemic disorders, and this new information is being applied in two clinical trials currently being conducted by Dr. Insogna and Dr. Thomas Carpenter from the Department of Pediatrics. These studies seek to determine the clinical and biochemical factors that lead to skeletal complications, such as enthesopathy and spinal ligament calcification, in this disease. Finally, Dr. Insogna and Dr. M. Tish Knobf from the School of Nursing are beginning an NIH-funded study to examine the impact of exercise on bone health in postmenopausal breast cancer survivors.
In the laboratory, Dr. Insogna’s interest focuses on cellular mechanisms of PTH-induced bone resorption and bone anabolism. He has had a long-standing interest in the role of interleukin-6 in mediating PTH-induced bone resorption. Current efforts in that area focus on the role of IL-6 in PTH-induced RANK ligand expression. Another major research effort in the laboratory is to define the role of the two Colony Stimulating Factor-1 (CSF1) isoforms in bone. Work from the Insogna laboratory has established that CSF1 is the major colony-stimulating factor released by osteoblasts in response to PTH. Further work supports the hypothesis that the soluble and membrane CSF1 isoforms serve non-redundant roles in bone. Selective deletion of each isoform in vivo is being pursued to better define their separate roles. As an example, we are currently examining the possibility that sCSF-1 has a unique role in estrogen-deficiency bone loss.
The laboratory is also interested in the effects of CSF1 in mature osteoclasts. CSF-1 is an important chemoattractant in vivo for osteoclasts, and the laboratory is exploring the molecular mechanisms by which CSF-1 induces cytoskeletal remodeling and osteoclast motility. The downstream targets for CSF1 in osteoclasts include PI 3-kinase, Rac1, LIM kinase 1, and cofilin. In the course of this work, the laboratory has identified unique interacting proteins that partner with Rac1, including BCA3, (Breast Cancer Associated Protein 3). The role of BCA3 is incompletely understood but one function appears to be a nuclear/cytoplasmic shuttle. This finding, in conjunction with an emerging nuclear role Rac1 suggests novel, hitherto unappreciated nuclear functions for Rac1 in osteoclasts. There is an ongoing interest in the laboratory in identifying environmental and genetic modifiers of PTH’s anabolic actions, which has lead to studies exploring the modulating effects of aging, diet and genes that regulate osteoclast function. Finally, the laboratory is interested in Wnt signaling and its role in lineage allocation in bone. Our current interest is in identifying Wnt-dependent metabolic pathways that regulate mesenchymal stem cell differentiation towards the osteoblast lineage and away from an adipocyte fate. For more information on Dr. Insogna's bench and clinical research, please visit https://medicine.yale.edu/lab/insogna.
Coauthors
Research Interests
Bone and Bones; Bone Resorption; Endocrinology; Hypophosphatemia, Familial; Musculoskeletal Diseases; Osteoblasts; Osteoclasts; Osteogenesis; Skeleton; Sphingosine; Wnt Signaling Pathway; Rickets, Hypophosphatemic
Selected Publications
- Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLHInsogna K, Sullivan R, Parziale S, Deng Y, Carrano D, Simpson C, Dufour S, Carpenter T, Petersen K. Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH. The Journal Of Clinical Endocrinology & Metabolism 2023, dgad642. PMID: 37930769, DOI: 10.1210/clinem/dgad642.
- Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked HypophosphatemiaSimpson C, Santoro A, Carpenter T, Deng Y, Parziale S, Insogna K. Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2023, 7: bvad116. PMID: 37860221, PMCID: PMC10583534, DOI: 10.1210/jendso/bvad116.
- Altered Expression of Several Molecular Mediators of Cerebrospinal Fluid Production in Hyp MiceKaplan J, Tommasini S, Yao G, Zhu M, Nishimura S, Ghazarian S, Louvi A, Insogna K. Altered Expression of Several Molecular Mediators of Cerebrospinal Fluid Production in Hyp Mice. Journal Of The Endocrine Society 2023, 7: bvad022. PMID: 36819458, PMCID: PMC9936957, DOI: 10.1210/jendso/bvad022.
- OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 StudyCarpenter T, Cimms T, Hetzer J, Insogna K, Kumar R, Merritt II J, Miller P, Peacock M, Rauch F, Stanciu I, Weber T, Jan De Beur S. OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study. Journal Of The Endocrine Society 2022, 6: a191-a191. PMCID: PMC9624705, DOI: 10.1210/jendso/bvac150.394.
- Epidemiology, Pathophysiology, and Genetics of Primary HyperparathyroidismMinisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. Journal Of Bone And Mineral Research 2022, 37: 2315-2329. PMID: 36245271, PMCID: PMC10092691, DOI: 10.1002/jbmr.4665.
- A Fragment-Specific Parathyroid Hormone Assay Improves Diagnosis of Normohormonal and Normocalcemic Primary HyperparathyroidismLee G, Ong C, Gibson C, Ogilvie J, Schneider E, Insogna K. A Fragment-Specific Parathyroid Hormone Assay Improves Diagnosis of Normohormonal and Normocalcemic Primary Hyperparathyroidism. Journal Of The American College Of Surgeons 2022, 235: s19-s19. DOI: 10.1097/01.xcs.0000895768.77835.44.
- Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked HypophosphatemiaWeber TJ, Imel EA, Carpenter TO, Peacock M, Portale AA, Hetzer J, Merritt JL, Insogna K. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 155-165. PMID: 36072994, PMCID: PMC9759172, DOI: 10.1210/clinem/dgac518.
- Differing effects of oral conjugated equine estrogen and transdermal estradiol on vitamin D metabolism in postmenopausal women: a 4-year longitudinal studySantoro AM, Simpson CA, Cong E, Haas A, Sullivan RR, Parziale S, Deng Y, Insogna KL. Differing effects of oral conjugated equine estrogen and transdermal estradiol on vitamin D metabolism in postmenopausal women: a 4-year longitudinal study. Menopause The Journal Of The North American Menopause Society 2022, 29: 1200-1203. PMID: 35969885, DOI: 10.1097/gme.0000000000002045.
- Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 StudyBrandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K, Ito N, Javaid K, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Portale A, Ralston SH, Tanaka H, Weber TJ, Yoo HW, Sun W, Williams A, Nixon A, Takeuchi Y. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcified Tissue International 2022, 111: 409-418. PMID: 35927518, DOI: 10.1007/s00223-022-01006-7.
- Correction to: The clinician’s guide to prevention and treatment of osteoporosisLeBoff M, Greenspan S, Insogna K, Lewiecki E, Saag K, Singer A, Siris E. Correction to: The clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International 2022, 33: 2243-2243. PMID: 35900384, PMCID: PMC9546943, DOI: 10.1007/s00198-022-06479-8.
- The clinician’s guide to prevention and treatment of osteoporosisLeBoff M, Greenspan S, Insogna K, Lewiecki E, Saag K, Singer A, Siris E. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International 2022, 33: 2049-2102. PMID: 35478046, PMCID: PMC9546973, DOI: 10.1007/s00198-021-05900-y.
- Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer CenterDosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756-4756. DOI: 10.1182/blood-2021-147466.
- Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey DataJavaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K, Imel EA. Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e1249-e1262. PMID: 34636401, PMCID: PMC8852215, DOI: 10.1210/clinem/dgab739.
- Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionBriot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 2021, 7: e001714. PMID: 34548383, PMCID: PMC8458321, DOI: 10.1136/rmdopen-2021-001714.
- Update on Osteoporosis Screening and ManagementAnam AK, Insogna K. Update on Osteoporosis Screening and Management. Medical Clinics Of North America 2021, 105: 1117-1134. PMID: 34688418, DOI: 10.1016/j.mcna.2021.05.016.
- Corticosteroid use in chronic dermatologic disorders and osteoporosisLupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. International Journal Of Women's Dermatology 2021, 7: 545-551. PMID: 35024411, PMCID: PMC8721058, DOI: 10.1016/j.ijwd.2021.07.014.
- Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thingde Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing. Journal Of Bone And Mineral Research 2021, 36: 2455-2456. PMID: 34030212, PMCID: PMC9290665, DOI: 10.1002/jbmr.4317.
- Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked HypophosphatemiaSimpson C, Santoro A, Carpenter T, Insogna K. Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2021, 5: a27-a27. PMCID: PMC8089365, DOI: 10.1210/jendso/bvab048.052.
- An Unanticipated Role for Sphingosine Kinase-2 in Bone and in the Anabolic Effect of Parathyroid HormoneWalker JM, Yao GQ, Siu E, Zhu M, Sun BH, Simpson C, Insogna KL. An Unanticipated Role for Sphingosine Kinase-2 in Bone and in the Anabolic Effect of Parathyroid Hormone. Endocrinology 2021, 162: bqab042. PMID: 33640975, PMCID: PMC8095390, DOI: 10.1210/endocr/bqab042.
- Selective deletion of the receptor for CSF1, c-fms, in osteoclasts results in a high bone mass phenotype, smaller osteoclasts in vivo and an impaired response to an anabolic PTH regimenZhu M, Sun BH, Nevius E, Kaplan J, Pereira J, Insogna K. Selective deletion of the receptor for CSF1, c-fms, in osteoclasts results in a high bone mass phenotype, smaller osteoclasts in vivo and an impaired response to an anabolic PTH regimen. PLOS ONE 2021, 16: e0247199. PMID: 33607650, PMCID: PMC7895546, DOI: 10.1371/journal.pone.0247199.
- Burosumab for the Treatment of Tumor‐Induced Osteomalaciade Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the Treatment of Tumor‐Induced Osteomalacia. Journal Of Bone And Mineral Research 2021, 36: 627-635. PMID: 33338281, PMCID: PMC8247961, DOI: 10.1002/jbmr.4233.
- Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trialKamenický P, Portale A, Carpenter T, Briot K, Imel E, Weber T, Pitukcheewanont P, Cheong H, de Beur S, Imanishi Y, Ito N, Lachmann R, Tanaka H, Perwad F, Zhang L, Skrinar A, Rees L, Insogna K, Investigators O. Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial. Bone Reports 2020, 13: 100654. DOI: 10.1016/j.bonr.2020.100654.
- New Therapies for Hypophosphatemia-Related to FGF23 ExcessAthonvarangkul D, Insogna KL. New Therapies for Hypophosphatemia-Related to FGF23 Excess. Calcified Tissue International 2020, 108: 143-157. PMID: 32504139, DOI: 10.1007/s00223-020-00705-3.
- OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 TrialPerwad F, Portale A, Carpenter T, Briot K, Imel E, Kamenicky P, Weber T, Pitukcheewanont P, Cheong H, De Beur S, Imanishi Y, Ito N, Lachmann R, Tanaka H, Zhang L, Skrinar A, Rees L, Insogna K. OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial. Journal Of The Endocrine Society 2020, 4: or29-01. PMCID: PMC7209551, DOI: 10.1210/jendso/bvaa046.147.
- SUN-333 Burosumab Improves Bone Density in Patients with X-Linked HypophosphatemiaMurari K, Insogna K. SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2020, 4: sun-333. PMCID: PMC7207437, DOI: 10.1210/jendso/bvaa046.1470.
- OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia SyndromeCarpenter T, Miller P, Weber T, Peacock M, Insogna K, Kumar R, Luca D, Cimms T, Roberts M, de Beur S. OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome. Journal Of The Endocrine Society 2020, 4: or29-06. PMCID: PMC7208350, DOI: 10.1210/jendso/bvaa046.403.
- Identification of a 22 bp DNA cis Element that Plays a Critical Role in Colony Stimulating Factor 1-Dependent Transcriptional Activation of the SPHK1 GeneYao GQ, Zhu M, Walker J, Insogna K. Identification of a 22 bp DNA cis Element that Plays a Critical Role in Colony Stimulating Factor 1-Dependent Transcriptional Activation of the SPHK1 Gene. Calcified Tissue International 2020, 107: 52-59. PMID: 32246175, PMCID: PMC7274855, DOI: 10.1007/s00223-020-00685-4.
- Corrigendum to “Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutation” [Bone Rep. 9 (2018) 154-158]Timme K, Rangel ES, Yuan Q, Wu D, Carpenter TO, Insogna K. Corrigendum to “Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutation” [Bone Rep. 9 (2018) 154-158]. Bone Reports 2020, 12: 100252. PMID: 32195293, PMCID: PMC7078292, DOI: 10.1016/j.bonr.2020.100252.
- Chapter 20 Phosphorus homeostasis and related disordersCarpenter T, Bergwitz C, Insogna K. Chapter 20 Phosphorus homeostasis and related disorders. 2020, 469-507. DOI: 10.1016/b978-0-12-814841-9.00020-8.
- Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International TrialInsogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial. Journal Of Bone And Mineral Research 2019, 34: 2183-2191. PMID: 31369697, PMCID: PMC6916280, DOI: 10.1002/jbmr.3843.
- Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodPortale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcified Tissue International 2019, 105: 271-284. PMID: 31165191, DOI: 10.1007/s00223-019-00568-3.
- OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia SyndromeJan De Beur S, Miller P, Weber T, Peacock M, Insogna K, Kumar R, Luca D, Theodore-Oklota C, Lampl K, San Martin J, Carpenter T. OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome. Journal Of The Endocrine Society 2019, 3: or13-1. PMCID: PMC6554835, DOI: 10.1210/js.2019-or13-1.
- Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemiaZhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L, Pang Q, Jiang Y, Li M, Wang O, He X, He S, Nie M, Xing X, Meng X, Zhou X, Yan L, Kaplan JM, Insogna KL, Xia W. Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. Bone 2019, 121: 212-220. PMID: 30682568, DOI: 10.1016/j.bone.2019.01.021.
- Primary HyperparathyroidismInsogna KL. Primary Hyperparathyroidism. New England Journal Of Medicine 2018, 379: e43. PMID: 30575486, DOI: 10.1056/nejmc1813648.
- Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutationAng K, Rangel E, Yuan Q, Wu D, Carpenter TO, Insogna K. Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutation. Bone Reports 2018, 9: 154-158. PMID: 30364642, PMCID: PMC6197702, DOI: 10.1016/j.bonr.2018.09.001.
- Primary HyperparathyroidismInsogna KL. Primary Hyperparathyroidism. New England Journal Of Medicine 2018, 379: 1050-1059. PMID: 30207907, DOI: 10.1056/nejmcp1714213.
- The contribution of cross-talk between the cell-surface proteins CD36 and CD47–TSP-1 in osteoclast formation and functionKoduru SV, Sun BH, Walker JM, Zhu M, Simpson C, Dhodapkar M, Insogna KL. The contribution of cross-talk between the cell-surface proteins CD36 and CD47–TSP-1 in osteoclast formation and function. Journal Of Biological Chemistry 2018, 293: 15055-15069. PMID: 30082316, PMCID: PMC6166722, DOI: 10.1074/jbc.ra117.000633.
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary AnalysisInsogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen C, Theodore‐Oklota C, Mealiffe M, San Martin J, Carpenter TO, Investigators O. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis. Journal Of Bone And Mineral Research 2018, 33: 1383-1393. PMID: 29947083, DOI: 10.1002/jbmr.3475.
- A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)Kamenicky P, Lachmann R, Carpenter T, Cohen-Solal M, Eastell R, Brandi M, Crowley R, Ralston S, Javaid M, Keen R, Briot K, Il C, Imanishi Y, Ito N, Tanaka H, Zhang L, Theodore-Oklota C, Mealiffe M, Martin J, Insogna K. A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH). Endocrine Abstracts 2018 DOI: 10.1530/endoabs.56.oc3.1.
- Abstract #512 A Phase 3 Randomized; Placebo-Controlled Study Investigating Burosumab for Adult X-Linked Hypophosphatemia (XLH)De Beur S, Carpenter T, Briot K, Imel E, Kamenický P, Ruppe M, Portale A, Weber T, Pitukcheewanont P, Cheong H, Imanishi Y, Ito N, Lachmann R, Tanaka H, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Abstract #512 A Phase 3 Randomized; Placebo-Controlled Study Investigating Burosumab for Adult X-Linked Hypophosphatemia (XLH). Endocrine Practice 2018, 24: 112. DOI: 10.1016/s1530-891x(20)47189-7.
- Animal versus plant protein and adult bone health: A systematic review and meta-analysis from the National Osteoporosis FoundationShams-White MM, Chung M, Fu Z, Insogna KL, Karlsen MC, LeBoff MS, Shapses SA, Sackey J, Shi J, Wallace TC, Weaver CM. Animal versus plant protein and adult bone health: A systematic review and meta-analysis from the National Osteoporosis Foundation. PLOS ONE 2018, 13: e0192459. PMID: 29474360, PMCID: PMC5825010, DOI: 10.1371/journal.pone.0192459.
- Associations among circulating colony-stimulating factor-1, estrogen, and bone mineral density in postmenopausal womenHaas AV, Cong E, Simpson CA, Sukumar N, Deng Y, Insogna KL. Associations among circulating colony-stimulating factor-1, estrogen, and bone mineral density in postmenopausal women. Menopause The Journal Of The North American Menopause Society 2018, 25: 197-201. PMID: 28816930, DOI: 10.1097/gme.0000000000000974.
- Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gapsHsieh E, Wang Q, Zhang R, Niu X, Xia W, Fraenkel L, Insogna KL, Li J, Smith JS, Zhou C, Qiao YL, Zhang P. Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps. BMC Cancer 2018, 18: 104. PMID: 29378534, PMCID: PMC5789645, DOI: 10.1186/s12885-018-4014-5.
- Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked HypophosphatemiaSullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. Calcified Tissue International 2018, 102: 666-670. PMID: 29383408, PMCID: PMC5957766, DOI: 10.1007/s00223-017-0382-0.
- Chapter 83 The Hypocalcemic DisordersGafni R, Insogna K, Carpenter T. Chapter 83 The Hypocalcemic Disorders. 2018, 527-547. DOI: 10.1016/b978-0-12-809963-6.00083-3.
- Selective deletion of the soluble Colony-Stimulating Factor 1 isoform in vivo prevents estrogen-deficiency bone loss in miceYao GQ, Troiano N, Simpson CA, Insogna KL. Selective deletion of the soluble Colony-Stimulating Factor 1 isoform in vivo prevents estrogen-deficiency bone loss in mice. Bone Research 2017, 5: 17022. PMID: 29152381, PMCID: PMC5684603, DOI: 10.1038/boneres.2017.22.
- The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomesKnobf MT, Jeon S, Smith B, Harris L, Thompson S, Stacy MR, Insogna K, Sinusas AJ. The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes. Heart & Lung 2017, 46: 375-381. PMID: 28803675, PMCID: PMC6129386, DOI: 10.1016/j.hrtlng.2017.06.001.
- Breast cancer-associated gene 3 interacts with Rac1 and augments NF-κB signaling in vitro, but has no effect on RANKL-induced bone resorption in vivoYao C, Yu KP, Philbrick W, Sun BH, Simpson C, Zhang C, Insogna K. Breast cancer-associated gene 3 interacts with Rac1 and augments NF-κB signaling in vitro, but has no effect on RANKL-induced bone resorption in vivo. International Journal Of Molecular Medicine 2017, 40: 1067-1077. PMID: 28791343, PMCID: PMC5593463, DOI: 10.3892/ijmm.2017.3091.
- Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working GroupWu CC, Econs MJ, DiMeglio LA, Insogna KL, Levine MA, Orchard PJ, Miller WP, Petryk A, Rush ET, Shoback DM, Ward LM, Polgreen LE. Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. The Journal Of Clinical Endocrinology & Metabolism 2017, 102: 3111-3123. PMID: 28655174, DOI: 10.1210/jc.2017-01127.
- The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance, and Body Composition in Postmenopausal American Women: An Ancillary Study from a Multicenter Protein Supplementation TrialStojkovic V, Simpson CA, Sullivan RR, Cusano AM, Kerstetter JE, Kenny AM, Insogna KL, Bihuniak JD. The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance, and Body Composition in Postmenopausal American Women: An Ancillary Study from a Multicenter Protein Supplementation Trial. Nutrients 2017, 9: 484. PMID: 28492492, PMCID: PMC5452214, DOI: 10.3390/nu9050484.
- Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation 1 , 2Shams-White MM, Chung M, Du M, Fu Z, Insogna KL, Karlsen MC, LeBoff MS, Shapses SA, Sackey J, Wallace TC, Weaver CM. Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation 1 , 2. American Journal Of Clinical Nutrition 2017, 105: 1528-1543. PMID: 28404575, DOI: 10.3945/ajcn.116.145110.
- Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasisFoer D, Zhu M, Cardone RL, Simpson C, Sullivan R, Nemiroff S, Lee G, Kibbey RG, Petersen KF, Insogna KL. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis. Osteoporosis International 2017, 28: 2011-2017. PMID: 28283687, PMCID: PMC6693506, DOI: 10.1007/s00198-017-3977-4.
- Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology & Metabolism 2016, 102: 914-922. PMID: 27935736, PMCID: PMC5460686, DOI: 10.1210/jc.2016-3237.
- Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIVHsieh E, Fraenkel L, Han Y, Xia W, Insogna KL, Yin MT, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. AIDS 2016, 30: 1935-1942. PMID: 27124896, PMCID: PMC4949136, DOI: 10.1097/qad.0000000000001131.
- The liver throws the skeleton a bone (resorption factor)Chung C, Insogna KL. The liver throws the skeleton a bone (resorption factor). Hepatology 2016, 64: 977-979. PMID: 27312397, PMCID: PMC4992574, DOI: 10.1002/hep.28688.
- Hypophosphatemia promotes lower rates of muscle ATP synthesisPesta DH, Tsirigotis DN, Befroy DE, Caballero D, Jurczak MJ, Rahimi Y, Cline GW, Dufour S, Birkenfeld AL, Rothman DL, Carpenter TO, Insogna K, Petersen KF, Bergwitz C, Shulman GI. Hypophosphatemia promotes lower rates of muscle ATP synthesis. The FASEB Journal 2016, 30: 3378-3387. PMID: 27338702, PMCID: PMC5024687, DOI: 10.1096/fj.201600473r.
- Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemiaRuppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Reports 2016, 5: 158-162. PMID: 28326356, PMCID: PMC4926842, DOI: 10.1016/j.bonr.2016.05.004.
- Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individualsHsieh E, Fraenkel L, Han Y, Xia W, Insogna K, Yin M, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals. Bone Abstracts 2016 DOI: 10.1530/boneabs.5.op20.
- Vertebral fractures among breast cancer survivors in ChinaHsieh E, Wang Q, Zhang R, Niu X, Li J, Zhou C, Qiao Y, Xia W, Fraenkel L, Insogna K, Smith J, Zhang P. Vertebral fractures among breast cancer survivors in China. Bone Abstracts 2016 DOI: 10.1530/boneabs.5.p129.
- Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individualsHsieh E, Fraenkel L, Han Y, Xia W, Insogna K, Yin M, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals. Bone Abstracts 2016 DOI: 10.1530/boneabs.5.p337.
- Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapyKnobf MT, Jeon S, Smith B, Harris L, Kerstetter J, Thompson AS, Insogna K. Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy. Breast Cancer Research And Treatment 2016, 155: 491-500. PMID: 26850265, DOI: 10.1007/s10549-016-3693-3.
- An Unusual Case of Rickets and How Whole Exome Sequencing Helped to Correct a DiagnosisPeter P, Brownstein C, Yao G, Olear E, Simpson C, Agrawal P, Carpenter T, Insogna K. An Unusual Case of Rickets and How Whole Exome Sequencing Helped to Correct a Diagnosis. AACE Clinical Case Reports 2016, 2: ee278-ee283. DOI: 10.4158/ep15944.cr.
- Deletion of Rac in Mature Osteoclasts Causes Osteopetrosis, an Age‐Dependent Change in Osteoclast Number, and a Reduced Number of Osteoblasts In VivoZhu M, Sun B, Saar K, Simpson C, Troiano N, Dallas SL, Tiede-Lewis L, Nevius E, Pereira JP, Weinstein RS, Tommasini SM, Insogna KL. Deletion of Rac in Mature Osteoclasts Causes Osteopetrosis, an Age‐Dependent Change in Osteoclast Number, and a Reduced Number of Osteoblasts In Vivo. Journal Of Bone And Mineral Research 2015, 31: 864-873. PMID: 26496249, PMCID: PMC4826801, DOI: 10.1002/jbmr.2733.
- AgRP Neurons Regulate Bone MassKim JG, Sun BH, Dietrich MO, Koch M, Yao GQ, Diano S, Insogna K, Horvath TL. AgRP Neurons Regulate Bone Mass. Cell Reports 2015, 13: 8-14. PMID: 26411686, PMCID: PMC5868421, DOI: 10.1016/j.celrep.2015.08.070.
- Bone Health and OsteoporosisLupsa BC, Insogna K. Bone Health and Osteoporosis. Endocrinology And Metabolism Clinics Of North America 2015, 44: 517-530. PMID: 26316240, DOI: 10.1016/j.ecl.2015.05.002.
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell ResponsesHo PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, Kleinstein SH, Abel ED, Insogna KL, Feske S, Locasale JW, Bosenberg MW, Rathmell JC, Kaech SM. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell 2015, 162: 1217-1228. PMID: 26321681, PMCID: PMC4567953, DOI: 10.1016/j.cell.2015.08.012.
- Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemiaZhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia. The Journal Of Clinical Pharmacology 2015, 56: 176-185. PMID: 26073451, PMCID: PMC5042055, DOI: 10.1002/jcph.570.
- Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease.Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, Simpson CA, Sterpka J, Dubrow R, Zhang JH, Carpenter TO. Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 3625-32. PMID: 26176801, PMCID: PMC4596038, DOI: 10.1210/jc.2015-2199.
- Dietary Protein and Vitamin D Intake and Risk of Falls: A Secondary Analysis of Postmenopausal Women from the Study of Osteoporotic FracturesLarocque SC, Kerstetter JE, Cauley JA, Insogna KL, Ensrud K, Lui LY, Allore HG. Dietary Protein and Vitamin D Intake and Risk of Falls: A Secondary Analysis of Postmenopausal Women from the Study of Osteoporotic Fractures. Journal Of Nutrition In Gerontology And Geriatrics 2015, 34: 305-318. PMID: 26267443, PMCID: PMC4547350, DOI: 10.1080/21551197.2015.1054574.
- Effects of dietary glycaemic properties on markers of inflammation, insulin resistance and body composition in postmenopausal womenStojkovic V, Simpson C, Sullivan R, Cusano A, Insogna K, Bihuniak J. Effects of dietary glycaemic properties on markers of inflammation, insulin resistance and body composition in postmenopausal women. Endocrine Abstracts 2015 DOI: 10.1530/endoabs.37.gp.13.03.
- Abstract P1-09-16: Exercise and the influence of endocrine therapy on cardiac and metabolic outcomes in breast cancer survivorsKnobf M, Harris L, Insogna K, Smith B, Jeon S. Abstract P1-09-16: Exercise and the influence of endocrine therapy on cardiac and metabolic outcomes in breast cancer survivors. 2015, p1-09-16-p1-09-16. DOI: 10.1158/1538-7445.sabcs14-p1-09-16.
- Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 2565-2573. PMID: 25919461, PMCID: PMC4495171, DOI: 10.1210/jc.2015-1551.
- The Effect of a Whey Protein Supplement on Bone Mass in Older Caucasian AdultsKerstetter JE, Bihuniak JD, Brindisi J, Sullivan RR, Mangano KM, Larocque S, Kotler BM, Simpson CA, Cusano A, Gaffney-Stomberg E, Kleppinger A, Reynolds J, Dziura J, Kenny AM, Insogna KL. The Effect of a Whey Protein Supplement on Bone Mass in Older Caucasian Adults. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 2214-2222. PMID: 25844619, PMCID: PMC4454800, DOI: 10.1210/jc.2014-3792.
- The effects of dietary protein and amino acids on skeletal metabolismBihuniak JD, Insogna KL. The effects of dietary protein and amino acids on skeletal metabolism. Molecular And Cellular Endocrinology 2015, 410: 78-86. PMID: 25843057, PMCID: PMC5852680, DOI: 10.1016/j.mce.2015.03.024.
- The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance and Body Composition in Postmenopausal WomenBihuniak J, Stojkovic V, Simpson C, Sullivan R, Cusano A, Insogna K. The Effect of Dietary Glycemic Properties on Markers of Inflammation, Insulin Resistance and Body Composition in Postmenopausal Women. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.lb235.
- Osteoporosis-Related knowledge, self-efficacy and health beliefs among Chinese women with breast cancerHsieh E, Wang Q, Niu X, Fraenkel L, Bradley E, Insogna K, Xia W, Smith J, Qiao Y, Zhang P. Osteoporosis-Related knowledge, self-efficacy and health beliefs among Chinese women with breast cancer. Annals Of Global Health 2015, 81: 204. DOI: 10.1016/j.aogh.2015.02.970.
- A Clinician's Guide to X‐Linked HypophosphatemiaCarpenter T, Imel E, Holm I, de Beur S, Insogna K. A Clinician's Guide to X‐Linked Hypophosphatemia. Journal Of Bone And Mineral Research 2015, 30: 394-394. DOI: 10.1002/jbmr.2440.
- Osteoporosis knowledge, self-efficacy, and health beliefs among Chinese individuals with HIVHsieh E, Fraenkel L, Bradley EH, Xia W, Insogna KL, Cui Q, Li K, Li T. Osteoporosis knowledge, self-efficacy, and health beliefs among Chinese individuals with HIV. Archives Of Osteoporosis 2014, 9: 201. PMID: 25487753, PMCID: PMC4269230, DOI: 10.1007/s11657-014-0201-4.
- Effect of 25(OH) vitamin D reference method procedure (RMP) alignment on clinical measurements obtained with the IDS-iSYS chemiluminescent-based automated analyzerSimpson CA, Cusano AM, Bihuniak J, Walker J, Insogna KL. Effect of 25(OH) vitamin D reference method procedure (RMP) alignment on clinical measurements obtained with the IDS-iSYS chemiluminescent-based automated analyzer. The Journal Of Steroid Biochemistry And Molecular Biology 2014, 148: 41-46. PMID: 25239596, DOI: 10.1016/j.jsbmb.2014.09.013.
- Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIVHsieh E, Fraenkel L, Xia W, Hu YY, Han Y, Insogna K, Yin MT, Xie J, Zhu T, Li T. Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV. Osteoporosis International 2014, 26: 1035-1044. PMID: 25224293, PMCID: PMC4334679, DOI: 10.1007/s00198-014-2874-3.
- Duodenal Absorption and Tissue Utilization of Dietary Heme and Nonheme Iron Differ in RatsCao C, Thomas CE, Insogna KL, O'Brien KO. Duodenal Absorption and Tissue Utilization of Dietary Heme and Nonheme Iron Differ in Rats. Journal Of Nutrition 2014, 144: 1710-1717. PMID: 25332470, PMCID: PMC4195416, DOI: 10.3945/jn.114.197939.
- Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled StudyCarpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, Gundberg CM, Insogna KL. Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3103-3111. PMID: 25029424, PMCID: PMC4154090, DOI: 10.1210/jc.2014-2017.
- Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5Simpson CA, Foer D, Lee GS, Bihuniak J, Sun B, Sullivan R, Belsky J, Insogna KL. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. Osteoporosis International 2014, 25: 2383-2388. PMID: 24927689, PMCID: PMC4659359, DOI: 10.1007/s00198-014-2767-5.
- Denosumab for Treatment of Hypercalcemia of MalignancyHu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for Treatment of Hypercalcemia of Malignancy. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3144-3152. PMID: 24915117, PMCID: PMC4154084, DOI: 10.1210/jc.2014-1001.
- A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemiaCarpenter T, Imel E, Ruppe M, Weber T, Klausner M, Wooddell M, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna K, Peacock M. A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia. Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp90.
- Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemiaZhang X, Carpenter T, Imel E, Ruppe M, Weber T, Klausner M, Kawakami T, Ito T, Humphrey J, Insogna K, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia. Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp91.
- Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and NephrocalcinosisDasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, Hanley DA, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Sävendahl L, Munns CF, Lee H, Jüppner H, Bergwitz C. Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. Journal Of The American Society Of Nephrology 2014, 25: 2366-2375. PMID: 24700880, PMCID: PMC4178443, DOI: 10.1681/asn.2013101085.
- Duodenal expression of heme and non‐heme iron transporters and tissue partitioning of dietary heme and non‐heme iron in a rat mode of iron overload (246.8)Cao C, Thomas C, Insogna K, O'Brien K. Duodenal expression of heme and non‐heme iron transporters and tissue partitioning of dietary heme and non‐heme iron in a rat mode of iron overload (246.8). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.246.8.
- Cannabinoid receptor expression in femora and tibiae of C57/blk6 mice fed DHA and relationship to bone ash and BMC (1032.2)Kim J, Insogna K, Watkins B. Cannabinoid receptor expression in femora and tibiae of C57/blk6 mice fed DHA and relationship to bone ash and BMC (1032.2). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.1032.2.
- Measurement of Plasma, Serum, and Platelet Serotonin in Individuals With High Bone Mass and Mutations in LRP5Lee GS, Simpson C, Sun B, Yao C, Foer D, Sullivan B, Matthes S, Alenina N, Belsky J, Bader M, Insogna KL. Measurement of Plasma, Serum, and Platelet Serotonin in Individuals With High Bone Mass and Mutations in LRP5. Journal Of Bone And Mineral Research 2014, 29: 976-981. PMID: 24038240, PMCID: PMC3935983, DOI: 10.1002/jbmr.2086.
- Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemiaCarpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. Journal Of Clinical Investigation 2014, 124: 1587-1597. PMID: 24569459, PMCID: PMC3973088, DOI: 10.1172/jci72829.
- A4.14 Increased bone turnover after switch to tenofovir + lopinavir/ritonavir in chinese HIV + patientsHsieh E, Fraenkel L, Xia W, Hu Y, Han Y, Insogna K, Yin M, Xie J, Zhu T, Li T. A4.14 Increased bone turnover after switch to tenofovir + lopinavir/ritonavir in chinese HIV + patients. Annals Of The Rheumatic Diseases 2014, 73: a62. DOI: 10.1136/annrheumdis-2013-205124.141.
- A4.15 Osteoporosis knowledge, self-efficacy, and health beliefs among chinese men and women with HIVHsieh E, Fraenkel L, Bradley E, Xia W, Qu C, Ling L, Insogna K, Li T. A4.15 Osteoporosis knowledge, self-efficacy, and health beliefs among chinese men and women with HIV. Annals Of The Rheumatic Diseases 2014, 73: a62. DOI: 10.1136/annrheumdis-2013-205124.142.
- Dietary Acid Load Is Associated With Lower Bone Mineral Density in Men With Low Intake of Dietary CalciumMangano KM, Walsh SJ, Kenny AM, Insogna KL, Kerstetter JE. Dietary Acid Load Is Associated With Lower Bone Mineral Density in Men With Low Intake of Dietary Calcium. Journal Of Bone And Mineral Research 2014, 29: 500-506. PMID: 23873776, PMCID: PMC3946957, DOI: 10.1002/jbmr.2053.
- Supplementing a Low-Protein Diet with Dibasic Amino Acids Increases Urinary Calcium Excretion in Young Women 1,2Bihuniak JD, Sullivan RR, Simpson CA, Caseria DM, Huedo-Medina TB, O’Brien K, Kerstetter JE, Insogna KL. Supplementing a Low-Protein Diet with Dibasic Amino Acids Increases Urinary Calcium Excretion in Young Women 1,2. Journal Of Nutrition 2014, 144: 282-288. PMID: 24431325, PMCID: PMC3927545, DOI: 10.3945/jn.113.185009.
- The Transcription Factor T-box 3 Regulates Colony-stimulating Factor 1-dependent Jun Dimerization Protein 2 Expression and Plays an Important Role in Osteoclastogenesis*Yao C, Yao GQ, Sun BH, Zhang C, Tommasini SM, Insogna K. The Transcription Factor T-box 3 Regulates Colony-stimulating Factor 1-dependent Jun Dimerization Protein 2 Expression and Plays an Important Role in Osteoclastogenesis*. Journal Of Biological Chemistry 2014, 289: 6775-6790. PMID: 24394418, PMCID: PMC3945339, DOI: 10.1074/jbc.m113.499210.
- Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic MalignanciesGucalp R, Insogna K, Hu M, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain R. Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies. Blood 2013, 122: 2536-2536. DOI: 10.1182/blood.v122.21.2536.2536.
- An investigation of the association between omega 3 FA and bone mineral density among older adults: results from the National Health and Nutrition Examination Survey years 2005–2008Mangano KM, Kerstetter JE, Kenny AM, Insogna KL, Walsh SJ. An investigation of the association between omega 3 FA and bone mineral density among older adults: results from the National Health and Nutrition Examination Survey years 2005–2008. Osteoporosis International 2013, 25: 1033-1041. PMID: 24121998, PMCID: PMC3969769, DOI: 10.1007/s00198-013-2501-8.
- Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate TreatmentHu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. Journal Of The National Cancer Institute 2013, 105: 1417-1420. PMID: 23990665, PMCID: PMC3776443, DOI: 10.1093/jnci/djt225.
- Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).Hu M, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Wang H, Braun A, Jain R. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM). Journal Of Clinical Oncology 2013, 31: e20512-e20512. DOI: 10.1200/jco.2013.31.15_suppl.e20512.
- EBI2 guides osteoclast precursors to bone niches and regulates osteoclastogenesis and bone mass homeostasis. (P5099)Nevius E, Horowitz M, Insogna K, Ishii M, Pereira J. EBI2 guides osteoclast precursors to bone niches and regulates osteoclastogenesis and bone mass homeostasis. (P5099). The Journal Of Immunology 2013, 190: 129.14-129.14. DOI: 10.4049/jimmunol.190.supp.129.14.
- Increasing dietary protein selectively upregulates the DMT1 isoform that contains an iron responsive elementThomas C, Yao G, O'Brien K, Kerstetter J, Insogna K. Increasing dietary protein selectively upregulates the DMT1 isoform that contains an iron responsive element. The FASEB Journal 2013, 27: lb284-lb284. DOI: 10.1096/fasebj.27.1_supplement.lb284.
- The effect of selective amino acid supplementation on calcium absorption during a low protein dietBihuniak J, Sullivan R, Simpson C, Caseria D, O'Brien K, Kerstetter J, Insogna K. The effect of selective amino acid supplementation on calcium absorption during a low protein diet. The FASEB Journal 2013, 27: lb283-lb283. DOI: 10.1096/fasebj.27.1_supplement.lb283.
- Differential effects of hepcidin on heme and nonheme iron absorption in a rat model of iron overloadCao C, Thomas C, Insogna K, O'Brien K. Differential effects of hepcidin on heme and nonheme iron absorption in a rat model of iron overload. The FASEB Journal 2013, 27: 634.18-634.18. DOI: 10.1096/fasebj.27.1_supplement.634.18.
- Dietary Protein-Induced Increases in Urinary Calcium Are Accompanied by Similar Increases in Urinary Nitrogen and Urinary Urea: A Controlled Clinical TrialBihuniak JD, Simpson CA, Sullivan RR, Caseria DM, Kerstetter JE, Insogna KL. Dietary Protein-Induced Increases in Urinary Calcium Are Accompanied by Similar Increases in Urinary Nitrogen and Urinary Urea: A Controlled Clinical Trial. Journal Of The Academy Of Nutrition And Dietetics 2013, 113: 447-451. PMID: 23438496, PMCID: PMC5868414, DOI: 10.1016/j.jand.2012.11.002.
- Increasing dietary protein acutely augments intestinal iron transporter expression and significantly increases iron absorption in ratsThomas CE, Gaffney‐Stomberg E, Sun B, O'Brien KO, Kerstetter JE, Insogna KL. Increasing dietary protein acutely augments intestinal iron transporter expression and significantly increases iron absorption in rats. The FASEB Journal 2013, 27: 2476-2483. PMID: 23447582, DOI: 10.1096/fj.12-221945.
- Claudins, dietary milk proteins, and intestinal barrier regulationKotler BM, Kerstetter JE, Insogna KL. Claudins, dietary milk proteins, and intestinal barrier regulation. Nutrition Reviews 2013, 71: 60-65. PMID: 23282252, DOI: 10.1111/j.1753-4887.2012.00549.x.
- LIM kinase 1 deficient mice have reduced bone massKawano T, Zhu M, Troiano N, Horowitz M, Bian J, Gundberg C, Kolodziejczak K, Insogna K. LIM kinase 1 deficient mice have reduced bone mass. Bone 2012, 52: 70-82. PMID: 23017662, PMCID: PMC3688839, DOI: 10.1016/j.bone.2012.09.024.
- Phosphorus-31 MRI of hard and soft solids using quadratic echo line-narrowingFrey MA, Michaud M, VanHouten JN, Insogna KL, Madri JA, Barrett SE. Phosphorus-31 MRI of hard and soft solids using quadratic echo line-narrowing. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 5190-5195. PMID: 22431609, PMCID: PMC3325667, DOI: 10.1073/pnas.1117293109.
- 253 The Parathyroid Glands, Hypercalcemia, and HypocalcemiaWysolmerski J, Insogna K. 253 The Parathyroid Glands, Hypercalcemia, and Hypocalcemia. 2012, 1591-1601. DOI: 10.1016/b978-1-4377-1604-7.00253-0.
- Selective deletion of the membrane-bound colony stimulating factor 1 isoform leads to high bone mass but does not protect against estrogen-deficiency bone lossYao GQ, Wu JJ, Troiano N, Zhu ML, Xiao XY, Insogna K. Selective deletion of the membrane-bound colony stimulating factor 1 isoform leads to high bone mass but does not protect against estrogen-deficiency bone loss. Journal Of Bone And Mineral Metabolism 2011, 30: 408-418. PMID: 22105655, PMCID: PMC4378684, DOI: 10.1007/s00774-011-0336-y.
- Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter StudyHu M, Gucalp R, Insogna K, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Ying W, Yeh H. Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study. Blood 2011, 118: 2483-2483. DOI: 10.1182/blood.v118.21.2483.2483.
- Dietary Protein’s Impact on Skeletal HealthSurdykowski A, Kenney A, Insogna K, Kerstetter J. Dietary Protein’s Impact on Skeletal Health. 2011, 237-246. DOI: 10.1201/b11228-18.
- A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates.Hu M, Gucalp R, Insogna K, Glezerman I, Bone H, Jaccard A, Misiorowski W, Yu B, Yeh H. A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. Journal Of Clinical Oncology 2011, 29: tps245-tps245. DOI: 10.1200/jco.2011.29.15_suppl.tps245.
- A clinician's guide to X‐linked hypophosphatemiaCarpenter TO, Imel EA, Holm IA, de Beur S, Insogna KL. A clinician's guide to X‐linked hypophosphatemia. Journal Of Bone And Mineral Research 2011, 26: 1381-1388. PMID: 21538511, PMCID: PMC3157040, DOI: 10.1002/jbmr.340.
- Calcium Intake in the United States from Dietary and Supplemental Sources across Adult Age Groups: New Estimates from the National Health and Nutrition Examination Survey 2003-2006Mangano KM, Walsh SJ, Insogna KL, Kenny AM, Kerstetter JE. Calcium Intake in the United States from Dietary and Supplemental Sources across Adult Age Groups: New Estimates from the National Health and Nutrition Examination Survey 2003-2006. Journal Of The Academy Of Nutrition And Dietetics 2011, 111: 687-695. PMID: 21515114, PMCID: PMC3896234, DOI: 10.1016/j.jada.2011.02.014.
- Calcitonin Administration in X-Linked HypophosphatemiaLiu ES, Carpenter TO, Gundberg CM, Simpson CA, Insogna KL. Calcitonin Administration in X-Linked Hypophosphatemia. New England Journal Of Medicine 2011, 364: 1678-1680. PMID: 21524226, PMCID: PMC3162370, DOI: 10.1056/nejmc1010928.
- Using urinary nitrogen and urea to predict dietary protein intake: a controlled clinical trialBihuniak J, Simpson C, Sullivan R, Kerstetter J, Insogna K. Using urinary nitrogen and urea to predict dietary protein intake: a controlled clinical trial. The FASEB Journal 2011, 25: 600.3-600.3. DOI: 10.1096/fasebj.25.1_supplement.600.3.
- Dietary protein upregulates fractional intestinal iron absorption and directly increases DMT1 transcript and protein expressionCucchi C, Gaffney‐Stomberg E, Sun B, O'Brien K, Kerstetter J, Insogna K. Dietary protein upregulates fractional intestinal iron absorption and directly increases DMT1 transcript and protein expression. The FASEB Journal 2011, 25: lb193-lb193. DOI: 10.1096/fasebj.25.1_supplement.lb193.
- Dietary protein increases intestinal calcium absorption in part by increasing tight junction expression of Claudin‐2Gaffney‐Stomberg E, Cucchi C, Sun B, Bataille A, Renfro L, Kerstetter J, Insogna K. Dietary protein increases intestinal calcium absorption in part by increasing tight junction expression of Claudin‐2. The FASEB Journal 2011, 25: 983.30-983.30. DOI: 10.1096/fasebj.25.1_supplement.983.30.
- Calcium intake in the United States from dietary and supplemental sources across adult age groups: new estimates from NHANES 2003–2006Mangano K, Walsh S, Insogna K, Kenny A, Kerstetter J. Calcium intake in the United States from dietary and supplemental sources across adult age groups: new estimates from NHANES 2003–2006. The FASEB Journal 2011, 25: 993.1-993.1. DOI: 10.1096/fasebj.25.1_supplement.993.1.
- Control of bone formation by the serpentine receptor Frizzled-9Albers J, Schulze J, Beil FT, Gebauer M, Baranowsky A, Keller J, Marshall RP, Wintges K, Friedrich FW, Priemel M, Schilling AF, Rueger JM, Cornils K, Fehse B, Streichert T, Sauter G, Jakob F, Insogna KL, Pober B, Knobeloch KP, Francke U, Amling M, Schinke T. Control of bone formation by the serpentine receptor Frizzled-9. Journal Of Cell Biology 2011, 192: 1057-1072. PMID: 21402791, PMCID: PMC3063134, DOI: 10.1083/jcb.201008012.
- Dietary protein and skeletal health: a review of recent human researchKerstetter JE, Kenny AM, Insogna KL. Dietary protein and skeletal health: a review of recent human research. Current Opinion In Lipidology 2011, 22: 16-20. PMID: 21102327, PMCID: PMC4659357, DOI: 10.1097/mol.0b013e3283419441.
- Chapter 59 The Hypocalcemic Disorders Differential Diagnosis and Therapeutic Use of Vitamin DCarpenter T, Insogna K. Chapter 59 The Hypocalcemic Disorders Differential Diagnosis and Therapeutic Use of Vitamin D. 2011, 1091-1106. DOI: 10.1016/b978-0-12-381978-9.10059-9.
- Osteoclasts Lacking Rac2 Have Defective Chemotaxis and Resorptive ActivityItokowa T, Zhu ML, Troiano N, Bian J, Kawano T, Insogna K. Osteoclasts Lacking Rac2 Have Defective Chemotaxis and Resorptive Activity. Calcified Tissue International 2010, 88: 75-86. PMID: 21110188, PMCID: PMC3155765, DOI: 10.1007/s00223-010-9435-3.
- Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e352-7. PMID: 20685863, PMCID: PMC2968736, DOI: 10.1210/jc.2010-0589.
- Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in miceYao GQ, Wu JJ, Troiano N, Insogna K. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. Journal Of Bone And Mineral Metabolism 2010, 29: 141-148. PMID: 20602130, PMCID: PMC3457021, DOI: 10.1007/s00774-010-0202-3.
- Optimizing bone health in older adults: the importance of dietary proteinSurdykowski AK, Kenny AM, Insogna KL, Kerstetter JE. Optimizing bone health in older adults: the importance of dietary protein. Aging Health 2010, 6: 345-357. PMID: 20657805, PMCID: PMC2907525, DOI: 10.2217/ahe.10.16.
- Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trialWright MJ, Sullivan RR, Gaffney‐Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial. Journal Of Bone And Mineral Research 2010, 25: 2205-2211. PMID: 20499372, PMCID: PMC3312746, DOI: 10.1002/jbmr.108.
- Six Weeks of a Low Protein Diet Impairs Calcium HomeostasisSullivan R, Rosewater I, Caseria D, O'Brien K, Kerstetter J, Insogna K. Six Weeks of a Low Protein Diet Impairs Calcium Homeostasis. The FASEB Journal 2010, 24: lb356-lb356. DOI: 10.1096/fasebj.24.1_supplement.lb356.
- A High Protein Diet Induces Intestinal Iron Transporter Expression and Improves Iron Absorption in RatsCucchi C, Gaffney‐Stomberg E, Sun B, Kerstetter J, Insogna K. A High Protein Diet Induces Intestinal Iron Transporter Expression and Improves Iron Absorption in Rats. The FASEB Journal 2010, 24: 229.1-229.1. DOI: 10.1096/fasebj.24.1_supplement.229.1.
- The Effect of Dietary Protein on Intestinal Calcium Absorption in RatsGaffney-Stomberg E, Sun BH, Cucchi CE, Simpson CA, Gundberg C, Kerstetter JE, Insogna KL. The Effect of Dietary Protein on Intestinal Calcium Absorption in Rats. Endocrinology 2010, 151: 1071-1078. PMID: 20147526, PMCID: PMC2840679, DOI: 10.1210/en.2009-0744.
- Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone diseaseKukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009, 114: 3413-3421. PMID: 19661269, PMCID: PMC2765677, DOI: 10.1182/blood-2009-03-211920.
- Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp MiceLiang G, Katz LD, Insogna KL, Carpenter TO, Macica CM. Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice. Calcified Tissue International 2009, 85: 235-246. PMID: 19609735, PMCID: PMC2988401, DOI: 10.1007/s00223-009-9270-6.
- Increasing Dietary Protein Requirements in Elderly People for Optimal Muscle and Bone HealthGaffney‐Stomberg E, Insogna KL, Rodriguez NR, Kerstetter JE. Increasing Dietary Protein Requirements in Elderly People for Optimal Muscle and Bone Health. Journal Of The American Geriatrics Society 2009, 57: 1073-1079. PMID: 19460090, DOI: 10.1111/j.1532-5415.2009.02285.x.
- A Rodent Model to Evaluate the Effect of Dietary Protein on Intestinal Calcium AbsorptionGaffney‐Stomberg E, Cucchi C, Sun B, Simpson C, Kerstetter J, Insogna K. A Rodent Model to Evaluate the Effect of Dietary Protein on Intestinal Calcium Absorption. The FASEB Journal 2009, 23: 726.1-726.1. DOI: 10.1096/fasebj.23.1_supplement.726.1.
- LDL-Receptor Related Protein Five Controls Bone Formation by Inhibiting Serotonin Synthesis in the DuodenumYadav V, Ryu J, Suda N, Tanaka K, Gingrich J, Schütz G, Glorieux F, Chiang C, Zajac J, Insogna K, Mann J, Hen R, Ducy P, Karsenty G. LDL-Receptor Related Protein Five Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Obstetrical & Gynecological Survey 2009, 64: 240-242. DOI: 10.1097/01.ogx.0000345723.85624.24.
- The Effect of Proton Pump-Inhibiting Drugs on Mineral MetabolismInsogna KL. The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism. The American Journal Of Gastroenterology 2009, 104: ajg200944. PMID: 19262542, DOI: 10.1038/ajg.2009.44.
- The Effect of Proton Pump-Inhibiting Drugs on Mineral MetabolismInsogna K. The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism. The American Journal Of Gastroenterology 2009, 104: s2-s4. DOI: 10.14309/00000434-200903002-00002.
- Targeted overexpression of the two colony-stimulating factor-1 isoforms in osteoblasts differentially affects bone loss in ovariectomized miceYao GQ, Wu JJ, Ovadia S, Troiano N, Sun BH, Insogna K. Targeted overexpression of the two colony-stimulating factor-1 isoforms in osteoblasts differentially affects bone loss in ovariectomized mice. AJP Endocrinology And Metabolism 2009, 296: e714-e720. PMID: 19141689, PMCID: PMC2670621, DOI: 10.1152/ajpendo.90631.2008.
- Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in BoneWilliams BO, Insogna KL. Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone. Journal Of Bone And Mineral Research 2008, 24: 171-178. PMID: 19072724, PMCID: PMC3276354, DOI: 10.1359/jbmr.081235.
- Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip FractureMiki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM. Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip Fracture. Journal Of Bone And Joint Surgery 2008, 90: 2346-2353. PMID: 18978403, DOI: 10.2106/jbjs.g.01246.
- Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the DuodenumYadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum. Cell 2008, 135: 825-837. PMID: 19041748, PMCID: PMC2614332, DOI: 10.1016/j.cell.2008.09.059.
- A Patient With Hypophosphatemia, a Femoral Fracture, and Recurrent Kidney Stones: Report of a Novel Mutation in SLC34A3Page K, Bergwitz C, Jaureguiberry G, Harinarayan CV, Insogna K. A Patient With Hypophosphatemia, a Femoral Fracture, and Recurrent Kidney Stones: Report of a Novel Mutation in SLC34A3. Endocrine Practice 2008, 14: 869-874. PMID: 18996815, PMCID: PMC2773288, DOI: 10.4158/ep.14.7.869.
- An Aerobic Weight-Loaded Pilot Exercise Intervention for Breast Cancer Survivors: Bone Remodeling and Body Composition OutcomesKnobf MT, Insogna K, DiPietro L, Fennie K, Thompson AS. An Aerobic Weight-Loaded Pilot Exercise Intervention for Breast Cancer Survivors: Bone Remodeling and Body Composition Outcomes. Biological Research For Nursing 2008, 10: 34-43. PMID: 18705153, PMCID: PMC3540790, DOI: 10.1177/1099800408320579.
- Orthopaedic Management Improves the Early Rate of Osteoporosis Treatment After Hip Fracture: A Randomized Clinical TrialMiki R, Oetgen M, Kirk J, Insogna K, Lindskog D. Orthopaedic Management Improves the Early Rate of Osteoporosis Treatment After Hip Fracture: A Randomized Clinical Trial. Journal Of Clinical Densitometry 2008, 11: 463. DOI: 10.1016/j.jocd.2008.05.069.
- The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout MiceKawano T, Troiano N, Adams DJ, Wu JJ, Sun BH, Insogna K. The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice. Endocrinology 2008, 149: 4009-4015. PMID: 18467443, PMCID: PMC2488220, DOI: 10.1210/en.2008-0034.
- Can serum pentosidine levels predict risk of vertebral fracture in patients with type 2 diabetes mellitus?Insogna K. Can serum pentosidine levels predict risk of vertebral fracture in patients with type 2 diabetes mellitus? Nature Reviews Endocrinology 2008, 4: 366-367. PMID: 18461065, DOI: 10.1038/ncpendmet0835.
- Expression and Synthesis of Bone Morphogenetic Proteins by Osteoclasts: A Possible Path to Anabolic Bone RemodelingGarimella R, Tague SE, Zhang J, Belibi F, Nahar N, Sun BH, Insogna K, Wang J, Anderson HC. Expression and Synthesis of Bone Morphogenetic Proteins by Osteoclasts: A Possible Path to Anabolic Bone Remodeling. Journal Of Histochemistry & Cytochemistry 2008, 56: 569-577. PMID: 18319273, PMCID: PMC2386763, DOI: 10.1369/jhc.2008.950394.
- Proton pump‐inhibiting drugs, calcium homeostasis, and bone healthWright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump‐inhibiting drugs, calcium homeostasis, and bone health. Nutrition Reviews 2008, 66: 103-108. PMID: 18254877, DOI: 10.1111/j.1753-4887.2008.00015.x.
- The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary HyperparathyroidismNakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2007, 93: 967-973. PMID: 18073309, PMCID: PMC2266956, DOI: 10.1210/jc.2007-1645.
- Impact of Glucose‐Dependent Insulinotropic Peptide on Age‐Induced Bone LossDing K, Shi X, Zhong Q, Kang B, Xie D, Bollag WB, Bollag RJ, Hill W, Washington W, Mi Q, Insogna K, Chutkan N, Hamrick M, Isales CM. Impact of Glucose‐Dependent Insulinotropic Peptide on Age‐Induced Bone Loss. Journal Of Bone And Mineral Research 2007, 23: 536-543. PMID: 18072880, PMCID: PMC2669161, DOI: 10.1359/jbmr.071202.
- Dietary protein increases intestinal calcium absorption and improves bone balance: An hypothesisKerstetter J, Gaffney E, O'Brien K, Caseria D, Insogna K. Dietary protein increases intestinal calcium absorption and improves bone balance: An hypothesis. International Congress Series 2007, 1297: 204-216. DOI: 10.1016/j.ics.2006.08.027.
- Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone massXie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007, 40: 1352-1360. PMID: 17321229, DOI: 10.1016/j.bone.2007.01.007.
- Breast Cancer–Associated Gene 3 (BCA3) Is a Novel Rac1‐Interacting ProteinYu K, Itokawa T, Zhu M, Syam S, Seth A, Insogna K. Breast Cancer–Associated Gene 3 (BCA3) Is a Novel Rac1‐Interacting Protein. Journal Of Bone And Mineral Research 2007, 22: 628-637. PMID: 17227220, DOI: 10.1359/jbmr.070105.
- Colony-Stimulating Factor-1 Increases Osteoclast Intracellular pH and Promotes Survival via the Electroneutral Na/HCO3 Cotransporter NBCn1Bouyer P, Sakai H, Itokawa T, Kawano T, Fulton CM, Boron WF, Insogna KL. Colony-Stimulating Factor-1 Increases Osteoclast Intracellular pH and Promotes Survival via the Electroneutral Na/HCO3 Cotransporter NBCn1. Endocrinology 2006, 148: 831-840. PMID: 17068143, DOI: 10.1210/en.2006-0547.
- Effects of glucose-dependent insulinotropic peptide on osteoclast functionZhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, Bollag WB, Bollag RJ, Hamrick M, Insogna K, Isales CM. Effects of glucose-dependent insulinotropic peptide on osteoclast function. AJP Endocrinology And Metabolism 2006, 292: e543-e548. PMID: 17003233, DOI: 10.1152/ajpendo.00364.2006.
- Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclastsSakai H, Chen Y, Itokawa T, Yu KP, Zhu ML, Insogna K. Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts. Bone 2006, 39: 1290-1301. PMID: 16950670, DOI: 10.1016/j.bone.2006.06.012.
- Meat and Soy Protein Affect Calcium Homeostasis in Healthy Women 1 , 2Kerstetter JE, Wall DE, O’Brien K, Caseria DM, Insogna KL. Meat and Soy Protein Affect Calcium Homeostasis in Healthy Women 1 , 2. Journal Of Nutrition 2006, 136: 1890-1895. PMID: 16772455, DOI: 10.1093/jn/136.7.1890.
- The Cell-Surface Isoform of Colony Stimulating Factor 1 (CSF1) Restores but Does Not Completely Normalize Fecundity in CSF1-Deficient Mice1Ovadia S, Insogna K, Yao GQ. The Cell-Surface Isoform of Colony Stimulating Factor 1 (CSF1) Restores but Does Not Completely Normalize Fecundity in CSF1-Deficient Mice1. Biology Of Reproduction 2005, 74: 331-336. PMID: 16237150, DOI: 10.1095/biolreprod.105.045047.
- Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnoverXie D, Cheng H, Hamrick M, Zhong Q, Ding KH, Correa D, Williams S, Mulloy A, Bollag W, Bollag RJ, Runner RR, McPherson JC, Insogna K, Isales CM. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005, 37: 759-769. PMID: 16219496, DOI: 10.1016/j.bone.2005.06.021.
- Isotretinoin does have an adverse effect on bone mineral densityMilstone LM, Insogna KL, Leachman SA. Isotretinoin does have an adverse effect on bone mineral density. Journal Of The American Academy Of Dermatology 2005, 53: 181. PMID: 15965453, DOI: 10.1016/j.jaad.2005.03.025.
- l-Type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cellsBusque SM, Kerstetter JE, Geibel JP, Insogna K. l-Type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells. AJP Gastrointestinal And Liver Physiology 2005, 289: g664-g669. PMID: 15961860, DOI: 10.1152/ajpgi.00096.2005.
- CSF-1 Induces fos Gene Transcription and Activates the Transcription Factor Elk-1 in Mature OsteoclastsYao G, Itokawa T, Paliwal I, Insogna K. CSF-1 Induces fos Gene Transcription and Activates the Transcription Factor Elk-1 in Mature Osteoclasts. Calcified Tissue International 2005, 76: 371-378. PMID: 15812575, DOI: 10.1007/s00223-004-0099-8.
- Multiple melanocortin receptors are expressed in bone cellsZhong Q, Sridhar S, Ruan L, Ding KH, Xie D, Insogna K, Kang B, Xu J, Bollag RJ, Isales CM. Multiple melanocortin receptors are expressed in bone cells. Bone 2005, 36: 820-831. PMID: 15804492, DOI: 10.1016/j.bone.2005.01.020.
- CHAPTER 64 The Hypocalcemic Disorders: Differential Diagnosis and Therapeutic Use of Vitamin DCARPENTER T, INSOGNA K. CHAPTER 64 The Hypocalcemic Disorders: Differential Diagnosis and Therapeutic Use of Vitamin D. 2005, 1049-1063. DOI: 10.1016/b978-012252687-9/50067-x.
- The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone.Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J, Insogna K. The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 2004, 146: 1983-90. PMID: 15618351, DOI: 10.1210/en.2004-0770.
- Multisystem study of 20 older adults with Williams syndromeCherniske EM, Carpenter TO, Klaiman C, Young E, Bregman J, Insogna K, Schultz RT, Pober BR. Multisystem study of 20 older adults with Williams syndrome. American Journal Of Medical Genetics Part A 2004, 131A: 255-264. PMID: 15534874, DOI: 10.1002/ajmg.a.30400.
- Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing TumorsCarpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 1012-1020. PMID: 15562028, DOI: 10.1210/jc.2004-0357.
- The impact of dietary protein on calcium absorption and kinetic measures of bone turnover in women.Kerstetter JE, O'Brien KO, Caseria DM, Wall DE, Insogna KL. The impact of dietary protein on calcium absorption and kinetic measures of bone turnover in women. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 26-31. PMID: 15546911, DOI: 10.1210/jc.2004-0179.
- LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1Yang X, Yu K, Hao Y, Li DM, Stewart R, Insogna KL, Xu T. LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nature Cell Biology 2004, 6: 609-617. PMID: 15220930, DOI: 10.1038/ncb1140.
- The expanding role of PI3-kinase in boneGolden LH, Insogna KL. The expanding role of PI3-kinase in bone. Bone 2004, 34: 3-12. PMID: 14751558, DOI: 10.1016/j.bone.2003.09.005.
- Chapter 9 Calcium Homeostasis and Disorders of Calcium Metabolism During Pregnancy and LactationMasiukiewicz U, Insogna K. Chapter 9 Calcium Homeostasis and Disorders of Calcium Metabolism During Pregnancy and Lactation. 2004, 181-191. DOI: 10.1016/b978-0-7216-0435-0.50013-4.
- High Protein Diets, Calcium Economy, and Bone HealthKerstetter J, O'Brien K, Insogna K. High Protein Diets, Calcium Economy, and Bone Health. Topics In Clinical Nutrition 2004, 19: 57-70. DOI: 10.1097/00008486-200401000-00010.
- Dietary protein, calcium metabolism, and skeletal homeostasis revisitedKerstetter JE, O'Brien KO, Insogna KL. Dietary protein, calcium metabolism, and skeletal homeostasis revisited. American Journal Of Clinical Nutrition 2003, 78: s584-s592. PMID: 12936953, DOI: 10.1093/ajcn/78.3.584s.
- The Cell Surface Form of Colony-Stimulating Factor-1 Is Biologically Active in Bone in VivoYao GQ, Wu JJ, Sun BH, Troiano N, Mitnick MA, Insogna K. The Cell Surface Form of Colony-Stimulating Factor-1 Is Biologically Active in Bone in Vivo. Endocrinology 2003, 144: 3677-3682. PMID: 12865350, DOI: 10.1210/en.2002-221071.
- Torus palatinus: a new anatomical correlation with bone density in postmenopausal women.Belsky JL, Hamer JS, Hubert JE, Insogna K, Johns W. Torus palatinus: a new anatomical correlation with bone density in postmenopausal women. The Journal Of Clinical Endocrinology & Metabolism 2003, 88: 2081-6. PMID: 12727958, DOI: 10.1210/jc.2002-021726.
- Low Protein Intake: The Impact on Calcium and Bone Homeostasis in HumansKerstetter JE, O'Brien KO, Insogna KL. Low Protein Intake: The Impact on Calcium and Bone Homeostasis in Humans. Journal Of Nutrition 2003, 133: 855s-861s. PMID: 12612169, DOI: 10.1093/jn/133.3.855s.
- Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. Journal Of Bone And Mineral Research 2002, 17 Suppl 2: n108-16. PMID: 12412787.
- Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism.Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 4946-51. PMID: 12414855, DOI: 10.1210/jc.2001-011814.
- Overexpression of Parathyroid Hormone‐Related Protein Causes Hypercalcemia but Not Bone Metastases in a Murine Model of Mammary TumorigenesisWysolmerski JJ, Dann PR, Zelazny E, Dunbar ME, Insogna KL, Guise TA, Perkins AS. Overexpression of Parathyroid Hormone‐Related Protein Causes Hypercalcemia but Not Bone Metastases in a Murine Model of Mammary Tumorigenesis. Journal Of Bone And Mineral Research 2002, 17: 1164-1170. PMID: 12096830, DOI: 10.1359/jbmr.2002.17.7.1164.
- Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women.Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-8. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.
- High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5. New England Journal Of Medicine 2002, 346: 1513-1521. PMID: 12015390, DOI: 10.1056/nejmoa013444.
- A Role for Cell-Surface CSF-1 in Osteoblast-mediated OsteoclastogenesisYao G, Sun BH, Weir EC, Insogna KL. A Role for Cell-Surface CSF-1 in Osteoblast-mediated Osteoclastogenesis. Calcified Tissue International 2002, 70: 339-346. PMID: 12004339, DOI: 10.1007/s00223-001-1079-x.
- Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with AlendronateCruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.
- IL-6 negatively regulates IL-11 production in vitro and in vivo.Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K. IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 2001, 142: 3850-6. PMID: 11517162, DOI: 10.1210/endo.142.9.8368.
- PARAMETERS OF HIGH BONE-TURNOVER PREDICT BONE LOSS IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY1,2Cruz D, Wysolmerski J, Brickel H, Gundberg C, Simpson C, Mitnick M, Kliger A, Lorber M, Basadonna G, Friedman A, Insogna K, Bia M. PARAMETERS OF HIGH BONE-TURNOVER PREDICT BONE LOSS IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY1,2. Transplantation 2001, 72: 83-88. PMID: 11468539, DOI: 10.1097/00007890-200107150-00017.
- Dietary protein and intestinal calcium absorptionKerstetter J, O’Brien K, Insogna K. Dietary protein and intestinal calcium absorption. American Journal Of Clinical Nutrition 2001, 73: 990-991. PMID: 11333855, DOI: 10.1093/ajcn/73.5.990.
- Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptorMitnick M, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz M, Insogna K. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. AJP Endocrinology And Metabolism 2001, 280: e405-e412. PMID: 11171594, DOI: 10.1152/ajpendo.2001.280.3.e405.
- Chapter 25 Cytokines in Primary HyperparathyroidismNakchbandi I, Grey A, Masiukiewicz U, Mitnick M, Insogna K. Chapter 25 Cytokines in Primary Hyperparathyroidism. 2001, 411-421. DOI: 10.1016/b978-012098651-4/50027-4.
- POSTTRANSPLANT BONE DISEASE: EVIDENCE FOR A HIGH BONE RESORPTION STATECayco A, Wysolmerski J, Simpson C, Mitnick M, Gundberg C, Kliger A, Lorber M, Silver D, Basadonna G, Friedman A, Insogna K, Cruz D, Bia M. POSTTRANSPLANT BONE DISEASE: EVIDENCE FOR A HIGH BONE RESORPTION STATE. Transplantation 2000, 70: 1722-1728. PMID: 11152104, DOI: 10.1097/00007890-200012270-00011.
- Nuclear Factor-κB p50 Is Required for Tumor Necrosis Factor-α-Induced Colony-Stimulating Factor-1 Gene Expression in OsteoblastsYao G, Sun B, Insogna K, Weir E. Nuclear Factor-κB p50 Is Required for Tumor Necrosis Factor-α-Induced Colony-Stimulating Factor-1 Gene Expression in Osteoblasts. Endocrinology 2000, 141: 2914-2922. PMID: 10919279, DOI: 10.1210/endo.141.8.7592.
- Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro.Masiukiewicz US, Mitnick M, Grey AB, Insogna KL. Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro. Endocrinology 2000, 141: 2526-31. PMID: 10875254, DOI: 10.1210/endo.141.7.7537.
- A threshold for low-protein-diet–induced elevations in parathyroid hormone 1 , 2 , 3Kerstetter J, Svastisalee C, Caseria D, Mitnick M, Insogna K. A threshold for low-protein-diet–induced elevations in parathyroid hormone 1 , 2 , 3. American Journal Of Clinical Nutrition 2000, 72: 168-173. PMID: 10871576, DOI: 10.1093/ajcn/72.1.168.
- Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*Masiukiewicz U, Mitnick M, Grey A, Insogna K. Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*. Endocrinology 2000, 141: 2526-2531. DOI: 10.1210/endo.141.7.7537.
- Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1.Grey A, Chen Y, Paliwal I, Carlberg K, Insogna K. Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1. Endocrinology 2000, 141: 2129-38. PMID: 10830300, DOI: 10.1210/endo.141.6.7480.
- Evidence for a Functional Association between Phosphatidylinositol 3-Kinase and c-src in the Spreading Response of Osteoclasts to Colony-Stimulating Factor-1*Grey A, Chen Y, Paliwal I, Carlberg K, Insogna K. Evidence for a Functional Association between Phosphatidylinositol 3-Kinase and c-src in the Spreading Response of Osteoclasts to Colony-Stimulating Factor-1*. Endocrinology 2000, 141: 2129-2138. DOI: 10.1210/endo.141.6.7480.
- Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascadeNakchbandi I, Weir E, Insogna K, Philbrick W, Broadus A. Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 7296-7300. PMID: 10829073, PMCID: PMC16539, DOI: 10.1073/pnas.110553397.
- Low Dietary Protein and Low Bone DensityKerstetter JE, Looker AC, Insogna KL. Low Dietary Protein and Low Bone Density. Calcified Tissue International 2000, 66: 313-313. PMID: 10742451, DOI: 10.1007/s002230010062.
- A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in VivoGrey A, Mitnick M, Masiukiewicz U, Sun B, Rudikoff S, Jilka R, Manolagas S, Insogna K. A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo. Endocrinology 1999, 140: 4683-4690. PMID: 10499526, DOI: 10.1210/endo.140.10.7036.
- Bone Densities in Patients Receiving Isotretinoin for Cystic AcneLeachman SA, Insogna KL, Katz L, Ellison A, Milstone LM. Bone Densities in Patients Receiving Isotretinoin for Cystic Acne. JAMA Dermatology 1999, 135: 961-965. PMID: 10456346, DOI: 10.1001/archderm.135.8.961.
- Changes in bone turnover in young women consuming different levels of dietary protein.Kerstetter JE, Mitnick ME, Gundberg CM, Caseria DM, Ellison AF, Carpenter TO, Insogna KL. Changes in bone turnover in young women consuming different levels of dietary protein. The Journal Of Clinical Endocrinology & Metabolism 1999, 84: 1052-5. PMID: 10084594, DOI: 10.1210/jcem.84.3.5552.
- Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1Kerstetter J, Mitnick M, Gundberg C, Caseria D, Ellison A, Carpenter T, Insogna K. Changes in Bone Turnover in Young Women Consuming Different Levels of Dietary Protein1. The Journal Of Clinical Endocrinology & Metabolism 1999, 84: 1052-1055. DOI: 10.1210/jcem.84.3.5552.
- Dietary protein affects intestinal calcium absorption 1 , 2 – 3Kerstetter JE, O'Brien KO, Insogna KL. Dietary protein affects intestinal calcium absorption 1 , 2 – 3. American Journal Of Clinical Nutrition 1998, 68: 859-865. PMID: 9771863, DOI: 10.1093/ajcn/68.4.859.
- The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosisMasiukiewicz US, Insogna KL. The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging Clinical And Experimental Research 1998, 10: 232-239. PMID: 9801733, DOI: 10.1007/bf03339657.
- The Cell-surface Form of Colony-stimulating Factor-1 Is Regulated by Osteotropic Agents and Supports Formation of Multinucleated Osteoclast-like Cells*Yao G, Sun B, Hammond E, Spencer E, Horowitz M, Insogna K, Weir E. The Cell-surface Form of Colony-stimulating Factor-1 Is Regulated by Osteotropic Agents and Supports Formation of Multinucleated Osteoclast-like Cells*. Journal Of Biological Chemistry 1998, 273: 4119-4128. PMID: 9461606, DOI: 10.1074/jbc.273.7.4119.
- Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts.Insogna KL, Sahni M, Grey AB, Tanaka S, Horne WC, Neff L, Mitnick M, Levy JB, Baron R. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. Journal Of Clinical Investigation 1997, 100: 2476-2485. PMID: 9366562, PMCID: PMC508448, DOI: 10.1172/jci119790.
- Increased circulating concentrations of parathyroid hormone in healthy, young women consuming a protein-restricted dietKerstetter J, Caseria D, Mitnick M, Ellison A, Gay L, Liskov T, Carpenter T, Insogna K. Increased circulating concentrations of parathyroid hormone in healthy, young women consuming a protein-restricted diet. American Journal Of Clinical Nutrition 1997, 66: 1188-1196. PMID: 9356538, DOI: 10.1093/ajcn/66.5.1188.
- Parathyroid hormone increases circulating levels of fibronectin in vivo: modulating effect of ovariectomy.Sun BH, Mitnick M, Eielson C, Yao GQ, Paliwal I, Insogna K. Parathyroid hormone increases circulating levels of fibronectin in vivo: modulating effect of ovariectomy. Endocrinology 1997, 138: 3918-24. PMID: 9275082, DOI: 10.1210/endo.138.9.5421.
- Parathyroid Hormone Increases Circulating Levels of Fibronectin in Vivo: Modulating Effect of OvariectomySun B, Mitnick M, Eielson C, Yao G, Paliwal I, Insogna K. Parathyroid Hormone Increases Circulating Levels of Fibronectin in Vivo: Modulating Effect of Ovariectomy. Endocrinology 1997, 138: 3918-3924. DOI: 10.1210/endo.138.9.5421.
- Estrogen Replacement Therapy: New Options, Continuing Concerns-ReplyInsogna K, Concato J, Henrich J. Estrogen Replacement Therapy: New Options, Continuing Concerns-Reply. JAMA 1997, 277: 1516-1517. DOI: 10.1001/jama.1997.03540430028020.
- HRT Effects on BonesSperof L, Rowan J, Symons J, Cauley J, Lucas F, Kuller L, Insogna K, Concat J, Henrich J. HRT Effects on Bones. The Nurse Practitioner 1997, 22: 154-155. DOI: 10.1097/00006205-199702000-00019.
- Role of c‐Src in cellular events associated with colony‐stimulating factor‐1‐induced spreading in osteoclastsInsogna K, Tanaka S, Neff L, Horne W, Levy J, Baron R. Role of c‐Src in cellular events associated with colony‐stimulating factor‐1‐induced spreading in osteoclasts. Molecular Reproduction And Development 1997, 46: 104-108. PMID: 8981371, DOI: 10.1002/(sici)1098-2795(199701)46:1<104::aid-mrd16>3.0.co;2-2.
- Boning up on estrogen: new options, new concerns.Insogna K, Concato J, Henrich J. Boning up on estrogen: new options, new concerns. JAMA 1996, 276: 1430-2. PMID: 8892721, DOI: 10.1001/jama.276.17.1430.
- Boning Up on Estrogen: New Options, New ConcernsInsogna K, Concato J, Henrich J. Boning Up on Estrogen: New Options, New Concerns. JAMA 1996, 276: 1430-1432. DOI: 10.1001/jama.1996.03540170074037.
- Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center studyGrey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 3450-3454. PMID: 8855783, DOI: 10.1210/jcem.81.10.8855783.
- Colony stimulating factor‐1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone‐related proteinWeir E, Lowik C, Paliwal I, Insogna K. Colony stimulating factor‐1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone‐related protein. Journal Of Bone And Mineral Research 1996, 11: 1474-1481. PMID: 8889847, DOI: 10.1002/jbmr.5650111014.
- Effects of continuous glucocorticoid infusion on bone metabolism in the ratKing CS, Weir EC, Gundberg CW, Fox J, Insogna KL. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcified Tissue International 1996, 59: 184-191. PMID: 8694896, DOI: 10.1007/s002239900107.
- Designing an Outpatient Research Diet to Enhance Dietary ComplianceCaseria D, Gay L, Liskov T, Marshall L, Insogna K, Kerstetter J. Designing an Outpatient Research Diet to Enhance Dietary Compliance. Journal Of The Academy Of Nutrition And Dietetics 1996, 96: a77. DOI: 10.1016/s0002-8223(96)00582-2.
- Tumor necrosis factor‐α induces transcription of the colony‐stimulating factor‐1 gene in murine osteoblastsKaplan D, Eielson C, Horowitz M, Insogna K, Weir E. Tumor necrosis factor‐α induces transcription of the colony‐stimulating factor‐1 gene in murine osteoblasts. Journal Of Cellular Physiology 1996, 168: 199-208. PMID: 8647916, DOI: 10.1002/(sici)1097-4652(199607)168:1<199::aid-jcp24>3.0.co;2-1.
- 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study.Carpenter TO, Keller M, Schwartz D, Mitnick M, Smith C, Ellison A, Carey D, Comite F, Horst R, Travers R, Glorieux FH, Gundberg CM, Poole AR, Insogna KL. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 2381-8. PMID: 8964881, DOI: 10.1210/jcem.81.6.8964881.
- Letters to the EditorKerstetter J, Insogna K. Letters to the Editor. Nutrition Reviews 1996, 54: 66-67. PMID: 9053828, DOI: 10.1111/j.1753-4887.1996.tb03860.x.
- Optimal Calcium IntakeBilezikian J, Bailey L, Elmer P, Favus M, Go V, Goldring S, Holt L, Insogna K, Krimgold B, Mallette L, Shapiro J, St. Jeor S, Stern P, Tilley B, Yamamoto M, Abrams S, Ascherio A, Baron J, Bell N, Chrischilles E, Dawson-Hughes B, Heaney R, Holick M, Johnston C, Kleerekoper M, Lemann J, Levine R, Lindsay R, Looker A, Love B, Marcus R, Matkovic V, Melton L, Meunier P, Navia J, Nelson D, Orwoll E, Peck W, Recker R, Resnick L, Riggs B, Singer F, Slemenda C, Sowers M, Weaver C, Miller S, Willett W, Shulman L, Ben-Ari E, Bray E, Calvo M, Ernst N, Ferguson J, Grave G, Haddad J, Hall W, Heyse S, Van S. Hubbard, McGowan J, Perloff M, Pollack E, Reford M, Stark-Reed P. Optimal Calcium Intake. JAMA 1994, 272: 1942-1948. DOI: 10.1001/jama.1994.03520240070044.
- Estrogen modulates parathyroid hormone-induced fibronectin production in human and rat osteoblast-like cells.Eielson C, Kaplan D, Mitnick MA, Paliwal I, Insogna K. Estrogen modulates parathyroid hormone-induced fibronectin production in human and rat osteoblast-like cells. Endocrinology 1994, 135: 1639-44. PMID: 7925127, DOI: 10.1210/endo.135.4.7925127.
- Dietary hypercalciuria in patients with calcium oxalate kidney stonesBurtis W, Gay L, Insogna K, Ellison A, Broadus A. Dietary hypercalciuria in patients with calcium oxalate kidney stones. American Journal Of Clinical Nutrition 1994, 60: 424-429. PMID: 8074077, DOI: 10.1093/ajcn/60.3.424.
- Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia.Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. The Journal Of Clinical Endocrinology & Metabolism 1994, 78: 1378-83. PMID: 8200940, DOI: 10.1210/jcem.78.6.8200940.
- Parathyroid hormone-related protein: evidence for isoform- and tissue-specific posttranslational processing.Yang KH, dePapp AE, Soifer NE, Dreyer BE, Wu TL, Porter SE, Bellantoni M, Burtis WJ, Insogna KL, Broadus AE. Parathyroid hormone-related protein: evidence for isoform- and tissue-specific posttranslational processing. Biochemistry 1994, 33: 7460-9. PMID: 8003511, DOI: 10.1021/bi00189a054.
- Osteoporosis and aging: The continuing crisisInsogna K. Osteoporosis and aging: The continuing crisis. Aging Clinical And Experimental Research 1994, 6: 65-67. PMID: 7918732, DOI: 10.1007/bf03324215.
- Macrophage colony‐stimulating factor release and receptor expression in bone cellsWeir E, Horowitz M, Baron R, Centrella M, Kacinski B, Insogna K. Macrophage colony‐stimulating factor release and receptor expression in bone cells. Journal Of Bone And Mineral Research 1993, 8: 1507-1518. PMID: 8304053, DOI: 10.1002/jbmr.5650081214.
- Calcium and Kidney StonesBurtis WJ, Broadus AE, Insogna KL. Calcium and Kidney Stones. New England Journal Of Medicine 1993, 329: 508-509. PMID: 8332168, DOI: 10.1056/nejm199308123290716.
- Secondary Hyperparathyroidism in Patients With Ichthyosis Is Not Caused by Vitamin D Deficiency or Ingestion of RetinoidsMilstone L, Bale S, Insogna K. Secondary Hyperparathyroidism in Patients With Ichthyosis Is Not Caused by Vitamin D Deficiency or Ingestion of Retinoids. JAMA Dermatology 1993, 129: 648-648. PMID: 8481031, DOI: 10.1001/archderm.1993.01680260120024.
- Human granulosa-luteal cells secrete parathyroid hormone-related protein in vivo and in vitro.Gutmann JN, Burtis WJ, Dreyer BE, Andrade-Gordon P, Penzias AS, Polan ML, Insogna KL. Human granulosa-luteal cells secrete parathyroid hormone-related protein in vivo and in vitro. The Journal Of Clinical Endocrinology & Metabolism 1993, 76: 1314-8. PMID: 8496323, DOI: 10.1210/jcem.76.5.8496323.
- The Effects of Isotretinoin on the Axial Skeleton and the Retinoid Effect-ReplyMilstone L, Insogna K. The Effects of Isotretinoin on the Axial Skeleton and the Retinoid Effect-Reply. JAMA Dermatology 1992, 128: 1650-1650. DOI: 10.1001/archderm.1992.04530010086018.
- A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets.Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 879-85. PMID: 1517380, DOI: 10.1210/jcem.75.3.1517380.
- Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types.Soifer NE, Dee KE, Insogna KL, Burtis WJ, Matovcik LM, Wu TL, Milstone LM, Broadus AE, Philbrick WM, Stewart AF. Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types. Journal Of Biological Chemistry 1992, 267: 18236-18243. PMID: 1517251, DOI: 10.1016/s0021-9258(19)37178-9.
- Parathyroid hormone‐related protein stimulates prostaglandin E2 release from human osteoblast‐like cells: Modulating effect of peptide lengthMitnick M, Isales C, Paliwal I, Insogna K. Parathyroid hormone‐related protein stimulates prostaglandin E2 release from human osteoblast‐like cells: Modulating effect of peptide length. Journal Of Bone And Mineral Research 1992, 7: 887-896. PMID: 1332431, DOI: 10.1002/jbmr.5650070805.
- Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivoWeir E, Terwilliger G, Sartori L, Insogna K. Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo. Calcified Tissue International 1992, 51: 30-34. PMID: 1393774, DOI: 10.1007/bf00296214.
- Serum Parathyroid Hormone Level Is Elevated in Some Patients With Disorders of KeratinizationMilstone LM, Ellison AF, Insogna KL. Serum Parathyroid Hormone Level Is Elevated in Some Patients With Disorders of Keratinization. JAMA Dermatology 1992, 128: 926-930. PMID: 1320849, DOI: 10.1001/archderm.1992.01680170058005.
- Parathyroid hormone-related protein is a paracrine regulator of prostaglandin E2 and fibronectin production in skinInsogna K, Isales C, Milstone L. Parathyroid hormone-related protein is a paracrine regulator of prostaglandin E2 and fibronectin production in skin. Bone And Mineral 1992, 17: 125. DOI: 10.1016/0169-6009(92)91841-6.
- A prospective trial of phosphate and 1,25(OH)2D in symptomatic adults with X-linked hypohosphatemiaCarpenter T, Sullivan W, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25(OH)2D in symptomatic adults with X-linked hypohosphatemia. Bone And Mineral 1992, 17: 209. DOI: 10.1016/0169-6009(92)92170-u.
- Cross-cultural association between dietary animal protein and hip fracture: A hypothesisAbelow B, Holford T, Insogna K. Cross-cultural association between dietary animal protein and hip fracture: A hypothesis. Calcified Tissue International 1992, 50: 14-18. PMID: 1739864, DOI: 10.1007/bf00297291.
- Treatment of Sarcoidosis-Associated Hypercalcemia With KetoconazoleBia M, Insogna K. Treatment of Sarcoidosis-Associated Hypercalcemia With Ketoconazole. American Journal Of Kidney Diseases 1991, 18: 702-705. PMID: 1962657, DOI: 10.1016/s0272-6386(12)80613-5.
- Immunoaffinity purification of parathyroid hormone‐related protein from bovine milk and human keratinocyte‐conditioned mediumStewart A, Wu T, Insogna K, Milstone L, Burtis W. Immunoaffinity purification of parathyroid hormone‐related protein from bovine milk and human keratinocyte‐conditioned medium. Journal Of Bone And Mineral Research 1991, 6: 305-311. PMID: 2035357, DOI: 10.1002/jbmr.5650060313.
- Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydraseBrown G, Morris C, Mitnick M, Insogna K. Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase. Journal Of Bone And Mineral Research 1990, 5: 1037-1041. PMID: 1964358, DOI: 10.1002/jbmr.5650051007.
- The parathyroid hormone-related protein stimulates human osteoblast-like cells to secrete a 9,000 dalton bone-resorbing protein.Morris CA, Mitnick ME, Weir EC, Horowitz M, Kreider BL, Insogna KL. The parathyroid hormone-related protein stimulates human osteoblast-like cells to secrete a 9,000 dalton bone-resorbing protein. Endocrinology 1990, 126: 1783-5. PMID: 2307127, DOI: 10.1210/endo-126-3-1783.
- Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calciumCarpenter T, Insogna K, Boulware S, Mitnick M. Vitamin D metabolism in chronic childhood hypoparathyroidism: Evidence for a direct regulatory effect of calcium. The Journal Of Pediatrics 1990, 116: 252-257. PMID: 2299496, DOI: 10.1016/s0022-3476(05)82883-5.
- Humoral Hypercalcemia of Malignancy: The Role of Parathyroid Hormone-related ProteinInsogna K. Humoral Hypercalcemia of Malignancy: The Role of Parathyroid Hormone-related Protein. Endocrinology And Metabolism Clinics Of North America 1989, 18: 779-794. PMID: 2673773, DOI: 10.1016/s0889-8529(18)30366-9.
- Parathyroid hormone-related protein modulates the effect of transforming growth factor-beta on deoxyribonucleic acid and collagen synthesis in fetal rat bone cells.Centrella M, Canalis E, McCarthy TL, Stewart AF, Orloff JJ, Insogna KL. Parathyroid hormone-related protein modulates the effect of transforming growth factor-beta on deoxyribonucleic acid and collagen synthesis in fetal rat bone cells. Endocrinology 1989, 125: 199-208. PMID: 2737143, DOI: 10.1210/endo-125-1-199.
- Native and a synthetic analogue of the malignancy-associated parathyroid hormone-like protein have in vitro transforming growth factor-like properties.Insogna KL, Stewart AF, Morris CA, Hough LM, Milstone LM, Centrella M. Native and a synthetic analogue of the malignancy-associated parathyroid hormone-like protein have in vitro transforming growth factor-like properties. Journal Of Clinical Investigation 1989, 83: 1057-1060. PMID: 2537846, PMCID: PMC303783, DOI: 10.1172/jci113947.
- Synthetic parathyroid hormone-like protein-(1-74): biochemical and physiological characterization.Stewart AF, Elliot J, Burtis WJ, Wu T, Insogna KL. Synthetic parathyroid hormone-like protein-(1-74): biochemical and physiological characterization. Endocrinology 1989, 124: 642-8. PMID: 2912692, DOI: 10.1210/endo-124-2-642.
- Osteoblast-like cells secrete granulocyte-macrophage colony-stimulating factor in response to parathyroid hormone and lipopolysaccharide.Weir EC, Insogna KL, Horowitz MC. Osteoblast-like cells secrete granulocyte-macrophage colony-stimulating factor in response to parathyroid hormone and lipopolysaccharide. Endocrinology 1989, 124: 899-904. PMID: 2643512, DOI: 10.1210/endo-124-2-899.
- Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive HypercalciuriaInsogna K, Ellison A, Burtis W, Sartori L, Lang R, Broadus A. Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria. Investigative Urology 1989, 141: 269-273. PMID: 2913343, DOI: 10.1016/s0022-5347(17)40737-3.
- Synthesis of a gene encoding parathyroid hormone-like protein-(1-141): purification and biological characterization of the expressed protein.THORIKAY M, KRAMER S, REYNOLDS F, SORVILLO J, DOESCHER L, WU T, MORRIS C, BURTIS W, INSOGNA K, VALENZUELA D, STEWART A. Synthesis of a gene encoding parathyroid hormone-like protein-(1-141): purification and biological characterization of the expressed protein. Endocrinology 1989, 124: 111-8. PMID: 2535801, DOI: 10.1210/endo-124-1-111.
- Adenylate cyclase-stimulating, bone-resorbing and B TGF-like activities in canine apocrine cell adenocarcinoma of the anal sacWeir E, Centrella M, Matus R, Brooks M, Wu T, Insogna K. Adenylate cyclase-stimulating, bone-resorbing and B TGF-like activities in canine apocrine cell adenocarcinoma of the anal sac. Calcified Tissue International 1988, 43: 359-365. PMID: 3146425, DOI: 10.1007/bf02553279.
- Isolation of 16,000-dalton parathyroid hormone-like proteins from two animal tumors causing humoral hypercalcemia of malignancy.Weir EC, Burtis WJ, Morris CA, Brady TG, Insogna KL. Isolation of 16,000-dalton parathyroid hormone-like proteins from two animal tumors causing humoral hypercalcemia of malignancy. Endocrinology 1988, 123: 2744-51. PMID: 3197642, DOI: 10.1210/endo-123-6-2744.
- Renal phosphate transport in humoral hypercalcemia of malignancySartori L, Insogna KL, Barrett PQ. Renal phosphate transport in humoral hypercalcemia of malignancy. American Journal Of Physiology 1988, 255: f1078-f1084. PMID: 2974244, DOI: 10.1152/ajprenal.1988.255.6.f1078.
- Characterization of a parathyroid Hormonelike Peptide Secreted by Human KeratinocytesINSOGNA K, STWART A, IKEDA K, CENTRELLA M, MILSONE L. Characterization of a parathyroid Hormonelike Peptide Secreted by Human Keratinocytes. Annals Of The New York Academy Of Sciences 1988, 548: 146-159. PMID: 2470290, DOI: 10.1111/j.1749-6632.1988.tb18801.x.
- Humoral Hypercalcemia of CancerFlier J, Underhill L, Broadus A, Mangin M, Ikeda K, Insogna K, Weir E, Burtis W, Stewart A. Humoral Hypercalcemia of Cancer. New England Journal Of Medicine 1988, 319: 556-563. PMID: 3043221, DOI: 10.1056/nejm198809013190906.
- Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy.Ikeda K, Mangin M, Dreyer BE, Webb AC, Posillico JT, Stewart AF, Bander NH, Weir EC, Insogna KL, Broadus AE. Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. Journal Of Clinical Investigation 1988, 81: 2010-2014. PMID: 2454953, PMCID: PMC442656, DOI: 10.1172/jci113551.
- Influence of Furosemide on Parathyroid Hormone Levels in HyperparathyroidismPetit WA, Henrich J, Insogna KL, Mitnick ME, Broadus AE. Influence of Furosemide on Parathyroid Hormone Levels in Hyperparathyroidism. New England Journal Of Medicine 1988, 318: 644-645. PMID: 3344015, DOI: 10.1056/nejm198803103181019.
- In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice.Weir EC, Insogna KL, Brownstein DG, Bander NH, Broadus AE. In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. Journal Of Clinical Investigation 1988, 81: 818-821. PMID: 3343341, PMCID: PMC442531, DOI: 10.1172/jci113389.
- Humoral hypercalcemia of malignancy.Burtis WJ, Wu TL, Insogna KL, Stewart AF. Humoral hypercalcemia of malignancy. Annals Of Internal Medicine 1988, 108: 454-7. PMID: 3277518, DOI: 10.7326/0003-4819-108-3-454.
- Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.Stewart AF, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE. Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. Journal Of Clinical Investigation 1988, 81: 596-600. PMID: 3339131, PMCID: PMC329608, DOI: 10.1172/jci113358.
- Synthetic and partially-purified adenylate cyclase-stimulating proteins from tumors associated with humoral hypercalcemia of malignancy inhibit phosphate transport in a PTH-responsive renal cell line.Sartori L, Weir EC, Stewart AF, Broadus AE, Mangin M, Barrett PQ, Insogna KL. Synthetic and partially-purified adenylate cyclase-stimulating proteins from tumors associated with humoral hypercalcemia of malignancy inhibit phosphate transport in a PTH-responsive renal cell line. The Journal Of Clinical Endocrinology & Metabolism 1988, 66: 459-61. PMID: 3339117, DOI: 10.1210/jcem-66-2-459.
- Humoral hypercalcemia of malignancy in canine lymphosarcoma.Weir EC, Norrdin RW, Matus RE, Brooks MB, Broadus AE, Mitnick M, Johnston SD, Insogna KL. Humoral hypercalcemia of malignancy in canine lymphosarcoma. Endocrinology 1988, 122: 602-8. PMID: 2828006, DOI: 10.1210/endo-122-2-602.
- Effect of short-term somatostatin and long-term triiodothyronine administration in a child with nontumours inappropriate thyrotropin secretionIsales C, Tamborlane W, Gertner J, Genel M, Insogna K. Effect of short-term somatostatin and long-term triiodothyronine administration in a child with nontumours inappropriate thyrotropin secretion. The Journal Of Pediatrics 1988, 112: 51-55. PMID: 2891806, DOI: 10.1016/s0022-3476(88)80120-3.
- Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis.Insogna KL, Dreyer BE, Mitnick M, Ellison AF, Broadus AE. Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis. The Journal Of Clinical Endocrinology & Metabolism 1988, 66: 72-5. PMID: 3335611, DOI: 10.1210/jcem-66-1-72.
- Skin-derived fibroblasts respond to human parathyroid hormone-like adenylate cyclase-stimulating proteins.WU T, INSOGNA K, HOUGH L, MILSTONE L, STEWART A. Skin-derived fibroblasts respond to human parathyroid hormone-like adenylate cyclase-stimulating proteins. The Journal Of Clinical Endocrinology & Metabolism 1987, 65: 105-9. PMID: 3034948, DOI: 10.1210/jcem-65-1-105.
- Co-purification of transforming growth factor beta-like activity with PTH-like and bone-resorbing activities from a tumor associated with humoral hypercalcemia of malignancy.INSOGNA K, WEIR E, WU T, STEWART A, BROADUS A, BURTIS W, CENTRELLA M. Co-purification of transforming growth factor beta-like activity with PTH-like and bone-resorbing activities from a tumor associated with humoral hypercalcemia of malignancy. Endocrinology 1987, 120: 2183-5. PMID: 3494596, DOI: 10.1210/endo-120-5-2183.
- Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy.Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna KL, Weir EC, Broadus AE, Stewart AF. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. Journal Of Biological Chemistry 1987, 262: 7151-7156. PMID: 3584110, DOI: 10.1016/s0021-9258(18)48217-8.
- The relative potency of a human tumor‐derived PTH‐like adenylate cyclase‐stimulating preparation in three bioassaysStewart A, Wu T, Burtis W, Weir E, Broadus A, Insogna K. The relative potency of a human tumor‐derived PTH‐like adenylate cyclase‐stimulating preparation in three bioassays. Journal Of Bone And Mineral Research 1987, 2: 37-43. PMID: 3455155, DOI: 10.1002/jbmr.5650020107.
- Hypercalcemia of MalignancyInsogna KL, Broadus AE. Hypercalcemia of Malignancy. Annual Review Of Medicine 1987, 38: 241-256. PMID: 3555293, DOI: 10.1146/annurev.me.38.020187.001325.
- Concerning the Pathogenesis of Idiopathic Hypercalciuria1Broadus AE, Burtis WJ, Oren DA, Sartori L, Gay L, Ellison AF, Insogna KL. Concerning the Pathogenesis of Idiopathic Hypercalciuria1. 1987, 58: 127-136. PMID: 3691116, DOI: 10.1159/000414502.
- Primary hyperparathyroidism in a dog: biochemical, bone histomorphometric, and pathologic findings.Weir EC, Norrdin RW, Barthold SW, Meuten DJ, Pond MJ, Insogna KL. Primary hyperparathyroidism in a dog: biochemical, bone histomorphometric, and pathologic findings. Journal Of The American Veterinary Medical Association 1986, 189: 1471-4. PMID: 3804843.
- Frequency and partial characterization of adenylate cyclase‐stimulating activity in tumors associated with humoral hypercalcemia of malignancyStewart A, Insogna K, Burtis W, Aminiafshar A, Wu T, Weir E, Broadus A. Frequency and partial characterization of adenylate cyclase‐stimulating activity in tumors associated with humoral hypercalcemia of malignancy. Journal Of Bone And Mineral Research 1986, 1: 267-276. PMID: 2845726, DOI: 10.1002/jbmr.5650010305.
- Two species of adenylate cyclase-stimulating activity in a murine squamous carcinoma model of humoral hypercalcemia of malignancy.BURTIS W, BROADUS A, INSOGNA K, WEIR E, STEWART A. Two species of adenylate cyclase-stimulating activity in a murine squamous carcinoma model of humoral hypercalcemia of malignancy. Endocrinology 1986, 118: 1982-8. PMID: 3009144, DOI: 10.1210/endo-118-5-1982.
- A Parathyroid Hormone-Like Protein from Cultured Human KeratinocytesMerendino JJ, Insogna KL, Milstone LM, Broadus AE, Stewart AF. A Parathyroid Hormone-Like Protein from Cultured Human Keratinocytes. Science 1986, 231: 388-390. PMID: 2417317, DOI: 10.1126/science.2417317.
- Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of MalignancyGODSALL JW, BURTIS WJ, INSOGNA KL, BROADUS AE, STEWART AF. Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of Malignancy. 1986, 42: 705-750. PMID: 3016837, DOI: 10.1016/b978-0-12-571142-5.50021-5.
- Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of MalignancyGODSALL J, BURTIS W, INSOGNA K, BROADUS A, STEWART A. Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of Malignancy. 1986, 705-750. DOI: 10.1016/b978-0-12-571142-5.50021-5.
- Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary HyperparathyroidismInsogna K, Mitnick M, Stewart A, Burtis W, Mallette L, Broadus A. Sensitivity of the Parathyroid Hormone–1, 25-Dihydroxyvitamin D Axis to Variations in Calcium Intake in Patients with Primary Hyperparathyroidism. New England Journal Of Medicine 1985, 313: 1126-1130. PMID: 2995810, DOI: 10.1056/nejm198510313131805.
- Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria.INSOGNA K, BROADUS A, DREYER B, ELLISON A, GERTNER J. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. The Journal Of Clinical Endocrinology & Metabolism 1985, 61: 490-5. PMID: 2991323, DOI: 10.1210/jcem-61-3-490.
- Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia.ROSENTHAL N, INSOGNA K, GODSALL J, GAC A, SMALDONE L, WALDRON J, STEWART A. Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. The Journal Of Clinical Endocrinology & Metabolism 1985, 60: 29-33. PMID: 3871092, DOI: 10.1210/jcem-60-1-29.
- Evidence for Disordered Control of 1,25-Dihydroxyvitamin D Production in Absorptive HypercalciuriaBroadus A, Insogna K, Lang R, Ellison A, Dreyer B. Evidence for Disordered Control of 1,25-Dihydroxyvitamin D Production in Absorptive Hypercalciuria. Investigative Urology 1985, 133: 150. DOI: 10.1016/s0022-5347(17)48838-0.
- Vitamin D metabolism and bone histomorphometry in a patient with antacid-induced osteomalaciaGodsall J, Baron R, Insogna K. Vitamin D metabolism and bone histomorphometry in a patient with antacid-induced osteomalacia. The American Journal Of Medicine 1984, 77: 747-750. PMID: 6486152, DOI: 10.1016/0002-9343(84)90378-4.
- Evidence for Disordered Control of 1,25-Dihydroxyvitamin D Production in Absorptive HypercalciuriaBroadus A, Insogna K, Lang R, Ellison A, Dreyer B. Evidence for Disordered Control of 1,25-Dihydroxyvitamin D Production in Absorptive Hypercalciuria. New England Journal Of Medicine 1984, 311: 73-80. PMID: 6330548, DOI: 10.1056/nejm198407123110201.
- Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy.INSOGNA K, STEWART A, VIGNERY A, WEIR E, NAMNUM P, BARON R, KIRKWOOD J, DEFTOS L, BROADUS A. Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology 1984, 114: 888-96. PMID: 6546543, DOI: 10.1210/endo-114-3-888.
- Hypercalciuria as a metabolic disease.Insogna KL, Broadus AE. Hypercalciuria as a metabolic disease. Urologic Oncology Seminars And Original Investigations 1984, 2: 20-33. PMID: 6463459.
- A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria.BROADUS A, INSOGNA K, LANG R, MALLETTE L, ORENLANG D, GERTNER J, KLIGER A, ELLISON A. A consideration of the hormonal basis and phosphate leak hypothesis of absorptive hypercalciuria. The Journal Of Clinical Endocrinology & Metabolism 1984, 58: 161-9. PMID: 6546292, DOI: 10.1210/jcem-58-1-161.
- Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells.Rodan SB, Insogna KL, Vignery AM, Stewart AF, Broadus AE, D'Souza SM, Bertolini DR, Mundy GR, Rodan GA. Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. Journal Of Clinical Investigation 1983, 72: 1511-1515. PMID: 6685137, PMCID: PMC370436, DOI: 10.1172/jci111108.
- Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets.Insogna KL, Broadus AE, Gertner JM. Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets. Journal Of Clinical Investigation 1983, 71: 1562-1569. PMID: 6306051, PMCID: PMC370362, DOI: 10.1172/jci110912.
- Evidence for bidirectional net movement of creatinine in the rat kidneyNamnum P, Insogna K, Baggish D, Hayslett JP. Evidence for bidirectional net movement of creatinine in the rat kidney. American Journal Of Physiology 1983, 244: f719-f723. PMID: 6859263, DOI: 10.1152/ajprenal.1983.244.6.f719.
- Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy.Stewart AF, Insogna KL, Goltzman D, Broadus AE. Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1983, 80: 1454-1458. PMID: 6298791, PMCID: PMC393616, DOI: 10.1073/pnas.80.5.1454.
- Influence of pregnancy on immunoreactive parathyroid hormone levelsGillette M, Insogna K, Lewis A, Baran D. Influence of pregnancy on immunoreactive parathyroid hormone levels. Calcified Tissue International 1982, 34: 9-12. PMID: 6279256, DOI: 10.1007/bf02411200.
- Impaired response to acute phosphorus (P) deprivation in familial hypophosphatemic rickets (HR)Gertner J, Insogna K. Impaired response to acute phosphorus (P) deprivation in familial hypophosphatemic rickets (HR). Pediatric Research 1981, 15: 1542-1542. DOI: 10.1203/00006450-198112000-00045.
- Effect of age on serum immunoreactive parathyroid hormone and its biological effects.INSOGNA K, LEWIS A, LIPINSKI B, BRYANT C, BARAN D. Effect of age on serum immunoreactive parathyroid hormone and its biological effects. The Journal Of Clinical Endocrinology & Metabolism 1981, 53: 1072-5. PMID: 6270181, DOI: 10.1210/jcem-53-5-1072.
- Osteomalacia and Weakness From Excessive Antacid IngestionInsogna K, Bordley D, Caro J, Lockwood D. Osteomalacia and Weakness From Excessive Antacid Ingestion. JAMA 1980, 244: 2544-2546. PMID: 7431592, DOI: 10.1001/jama.1980.03310220042025.
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Musculoskeletal System | Tumor-induced Osteomalacia Disease Monitoring Program |
Diseases of the Kidney & Urinary Tract | The Impact of Phosphate Metabolism on Healthy Aging |